10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED June 30, 2014

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission file number 001-13795

AMERICAN VANGUARD CORPORATION

Delaware	95-2588080
(State or other jurisdiction of Incorporation or organization)	(I.R.S. Employer Identification Number)
4695 MacArthur Court, Newport Beach, California	92660
(Address of principal executive offices)	(Zip Code)

(949) 260-1200

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	x	Accelerated Filer	¨
Non-Accelerated Filer	¨	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Common Stock, $.10 Par Value—29,080,871 shares as of July 24, 2014.

AMERICAN VANGUARD CORPORATION

INDEX

		Page Number
PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Statements of Operations and Comprehensive Income for the three months and six months ended June 30, 2014 and 2013		3
	Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013		4
	Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March  31, 2014 and June 30, 2014		5
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2013		6
	Notes to Condensed Consolidated Financial Statements		7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		24
Item 4.	Controls and Procedures		24
PART II—OTHER INFORMATION			25
Item 1.	Legal Proceedings		25
Item 6.	Exhibits		27
SIGNATURES			28

2

PART I.  FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

	For the three months ended June 30						For the six months ended June 30
	2014			2013			2014			2013
Net sales	$	68,313		$	86,761		$	149,408		$	208,298
Cost of sales		42,253			44,695			94,443			112,451
Gross profit		26,060			42,066			54,965			95,847
Operating expenses		25,337			29,169			50,280			56,798
Operating income		723			12,897			4,685			39,049
Interest expense		857			701			1,488			1,248
Less interest capitalized		(13	)		(31	)		(31	)		(225	)
(Loss) income before income taxes and loss on equity investment		(121	)		12,227			3,228			38,026
Income taxes (benefit) expense		(160	)		3,961			856			12,941
Income before loss on equity investment		39			8,266			2,372			25,085
Deduct net loss from equity method investment		(68	)		—			(396	)		—
Net (loss) income		(29	)		8,266			1,976			25,085
Add back net loss attributable to non-controlling interest		174			120			328			216
Net income attributable to American Vanguard Corporation		145			8,386			2,304			25,301
Change in fair value of interest rate swaps		145			174			281			352
Foreign currency translation adjustment		92			(476	)		143			(69	)
Comprehensive income	$	382		$	8,084		$	2,728		$	25,584
Earnings per common share—basic	$	.01		$	.29		$	.08		$	.89
Earnings per common share—assuming dilution	$	.01		$	.29		$	.08		$	.88
Weighted average shares outstanding—basic		28,408			28,295			28,404			28,280
Weighted average shares outstanding—assuming dilution		28,795			28,886			28,877			28,884

See notes to the condensed consolidated financial statements.

3

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

ASSETS

	June 30, 2014			Dec. 31, 2013
Current assets:
Cash and cash equivalents	$	4,189		$	6,680
Receivables:
Trade, net of allowance for doubtful accounts of $414 and $392, respectively		73,239			74,060
Other		2,738			892
Total receivables		75,977			74,952
Inventories		175,240			139,830
Prepaid expenses		14,049			11,435
Income taxes receivable		10,230			10,088
Deferred income tax assets		6,521			6,521
Total current assets		286,206			249,506
Property, plant and equipment, net		51,621			52,468
Intangible assets, net of applicable amortization		103,865			107,007
Other assets		37,750			38,462
	$	479,442		$	447,443
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current installments of long-term debt	$	70		$	69
Current installments of other liabilities		1,440			2,132
Accounts payable		23,900			40,702
Deferred revenue		1,512			3,788
Accrued program costs		74,359			53,630
Accrued expenses and other payables		5,996			10,178
Total current liabilities		107,277			110,499
Long-term debt, excluding current installments		86,091			51,676
Other liabilities, excluding current installments		3,981			4,143
Deferred income tax liabilities		23,002			23,330
Total liabilities		220,351			189,648
Commitments and contingent liabilities
Stockholders’ equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued		—			—
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,528,400 shares at June 30, 2014 and 31,092,782 shares at December 31, 2013		3,153			3,109
Additional paid-in capital		63,380			60,160
Accumulated other comprehensive loss		(624	)		(1,048	)
Retained earnings		201,937			202,470
		267,846			264,691
Less treasury stock, at cost, 2,450,634 shares at June 30, 2014 and 2,380,634 shares at December 31, 2013		(8,269	)		(6,738	)
American Vanguard Corporation stockholders’ equity		259,577			257,953
Non-controlling interest		(486	)		(158	)
Total stockholders’ equity		259,091			257,795
	$	479,442		$	447,443

See notes to the condensed consolidated financial statements.

4

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

For The Three Months Ended March 31, 2014 and June 30, 2014

(Unaudited)

	Common Stock				Additional Paid-in Capital		Retained Earnings			Accumulated Other Comprehensive Loss			Non- Controlling Interest			Treasury Stock					Total
	Shares		Amount													Shares		Amount
Balance, December 31, 2013		31,092,782	$	3,109	$	60,160	$	202,470		$	(1,048	)	$	(158	)		2,380,634	$	(6,738	)	$	257,795
Stocks issued under ESPP		16,446		2		391		—			—			—			—		—			393
Cash dividends on common stock ($0.05 per share)		—		—		—		(1,417	)		—			—			—		—			(1,417	)
Foreign currency translation adjustment, net		—		—		—		—			51			—			—		—			51
Stock based compensation		—		—		768		—			—			—			—		—			768
Change in fair value of interest rate swaps		—		—		—		—			136			—			—		—			136
Stock options exercised and grants of restricted stock units		81,678		8		617		—			—			—			—		—			625
Excess tax benefits from share based payment arrangements		—		—		235		—			—			—			—		—			235
Shares repurchased		—		—		—		—			—			—			70,000		(1,531	)		(1,531	)
Net income (loss)		—		—		—		2,159			—			(154	)		—		—			2,005
Balance, March 31, 2014		31,190,906	$	3,119	$	62,171	$	203,212		$	(861	)	$	(312	)		2,450,634	$	(8,269	)	$	259,060
Cash dividends on common stock ($0.05 per share)		—		—		—		(1,420	)		—			—			—		—			(1,420	)
Foreign currency translation adjustment, net		—		—		—		—			92			—			—		—			92
Stock based compensation		—		—		1,038		—			—			—			—		—			1,038
Change in fair value of interest rate swaps		—		—		—		—			145			—			—		—			145
Stock options exercised and grants of restricted stock units		337,494		34		144		—			—			—			—		—			178
Excess tax benefits from share based payment arrangements		—		—		27		—			—			—			—		—			27
Net income (loss)		—		—		—		145			—			(174	)		—		—			(29	)
Balance, June 30, 2014		31,528,400	$	3,153	$	63,380	$	201,937		$	(624	)	$	(486	)		2,450,634	$	(8,269	)	$	259,091

See notes to the condensed consolidated financial statements.

5

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

For The Six Months Ended June 30, 2014 and 2013

(Unaudited)

Increase (decrease) in cash	2014			2013
Cash flows from operating activities:
Net income	$	1,976		$	25,085
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization of fixed and intangible assets		7,996			7,461
Amortization of other long term assets		3,027			1,802
Amortization of discounted liabilities		175			86
Stock-based compensation		1,806			1,747
Tax benefit from exercise of stock options		(262	)		(57	)
Loss from equity method investment		396			—
Gain on dilution of equity method investment		(256	)		—
Changes in assets and liabilities associated with operations:
(Increase) decrease in net receivables		(1,025	)		8,513
Increase in inventories		(35,410	)		(39,199	)
Increase in prepaid expenses and other assets		(5,069	)		(9,837	)
Decrease (increase) in income tax receivable		120			(1,404	)
Decrease in accounts payable		(16,521	)		(8,532	)
Decrease in deferred revenue		(2,276	)		(20,149	)
Increase in other payables and accrued expenses		16,264			54,529
Net cash (used in) provided by operating activities		(29,059	)		20,045
Cash flows from investing activities:
Capital expenditures		(3,954	)		(8,360	)
Investment		—			(3,687	)
Net cash used in investing activities		(3,954	)		(12,047	)
Cash flows from financing activities:
Net borrowings under line of credit agreement		34,450			40,750
Payments on long-term debt		—			(46,000	)
Payments on other long-term liabilities		(1,109	)		(1,238	)
Tax benefit from exercise of stock options		262			57
Decrease in other notes payable		—			(6,154	)
Repurchases of common stock		(1,531	)		—
Payment of cash dividends		(2,836	)		(1,976	)
Proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)		1,196			527
Net cash provided by (used in) financing activities		30,432			(14,034	)
Net decrease in cash and cash equivalents		(2,581	)		(6,036	)
Cash and cash equivalents at beginning of period		6,680			38,476
Effect of exchange rate changes on cash		90			(26	)
Cash and cash equivalents as of the end of the period	$	4,189		$	32,414

See notes to the condensed consolidated financial statements

6

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(In thousands, except share data)

(Unaudited)

1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

2. Property, plant and equipment (at cost) at June 30, 2014 and December 31, 2013 consists of the following:

	June 30, 2014			December 31, 2013
Land	$	2,458		$	2,458
Buildings and improvements		14,355			14,167
Machinery and equipment		105,815			94,184
Office furniture, fixtures and equipment		9,980			9,717
Automotive equipment		288			278
Construction in progress		2,477			10,615
		135,373			131,419
Less accumulated depreciation		(83,752	)		(78,951	)
	$	51,621		$	52,468

3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:

	June 30, 2014		December 31, 2013
Finished products	$	151,269	$	126,872
Raw materials		23,971		12,958
	$	175,240	$	139,830

4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Net sales:
Insecticides	$	34,524	$	39,218	$	80,961	$	118,085
Herbicides/soil fumigants/fungicides		13,926		24,699		36,857		57,685
Other, including plant growth regulators		8,929		13,228		12,736		16,919
		57,379		77,145		130,554		192,689
Non-crop		10,934		9,616		18,854		15,609
	$	68,313	$	86,761	$	149,408	$	208,298
	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Net sales:
US	$	50,094	$	67,837	$	108,050	$	170,942
International		18,219		18,924		41,358		37,356
	$	68,313	$	86,761	$	149,408	$	208,298

7

5. Accrued Program Costs - In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers as a reduction of sales. The Company describes these payments as “Programs.” Programs are a critical part of doing business in the agricultural chemicals business market place. For accounting purposes, programs are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicator-driven payments made to distributors, retailers or growers at the end of a growing season. Each quarter management compares each sale transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in the terms and conditions attached to each program. If management believes that customers are falling short of their annual goals, then periodic adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at the end of the crop season, at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

6. The Company has issued the following cash dividends in the periods covered by this Form 10-Q:

Declaration Date	Distribution Date	Record Date	Dividend Per Share		Total Paid
June 9, 2014	July 17, 2014	July 3, 2014	$	0.05	$	1,420
March 10, 2014	April 18, 2014	April 4, 2013	$	0.05	$	1,417
Total			$	0.10	$	2,837
June 10, 2013	July 19, 2013	July 5, 2013	$	0.05	$	1,413
March 11, 2013	April 19, 2013	April 5, 2013	$	0.07	$	1,976
Total			$	0.12	$	3,389

The Company announced the decision to begin making quarterly dividend payments on June 10, 2013. Previously, the Company made semi-annual dividend payments.

7. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260 Earnings Per Share (“EPS”) requires dual presentation of basic EPS and diluted EPS on the face of our condensed consolidated statements of operations and comprehensive income. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company’s common stock, are exercised.

The components of basic and diluted earnings per share were as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Numerator:
Net income attributable to AVD	$	145	$	8,386	$	2,304	$	25,301
Denominator:
Weighted averages shares outstanding-basic		28,408		28,295		28,404		28,280
Dilutive effect of stock options and grants		387		591		473		604
		28,795		28,886		28,877		28,884

The Company excluded 2,385 stock options from the computation of diluted earnings per share for the three months ended June 30, 2014 and 4,591 stock options from the computation of diluted earnings per share for the six months ended June 30, 2014, because they are anti-dilutive. For the three and six month ended June 30, 2013 no options were excluded from the computation.

8. Substantially all of the Company’s assets are pledged as collateral with its banks.

8

The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at June 30, 2014 and December 31, 2013. These are summarized in the following table:

Indebtedness	June 30, 2014						December 31, 2013
$000’s	Long-term		Short-term		Total		Long-term		Short-term		Total
Revolving line of credit	$	86,000	$	—	$	86,000	$	51,550	$	—	$	51,550
Notes payable		91		70		161		126		69		195
Total indebtedness	$	86,091	$	70	$	86,161	$	51,676	$	69	$	51,745

On June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit up to $200 million and an accordion feature for up to $100 million. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt. See, infra, Item 18 “Subsequent Events” regarding the first amendment to the New Credit Agreement.

At June 30, 2014, the Company had in place one interest rate swap contract with a notional amount of $33,000 that is accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap are reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Losses in other comprehensive income expected to be reclassified to earnings in the coming 12 months are $(59). Amounts recorded in earnings for hedge ineffectiveness for the period ending June 30, 2014 were immaterial.

The Company uses a pay fixed, receive 1Month LIBOR (London Interbank Offered Rate) interest rate swap to manage the interest expense generated by variable rate debt. At June 30, 2014 and 2013, the Company had in place an interest rate swap, the use of which results in a fixed interest rate of 3.39% for the portion of variable rate debt that is covered by the interest rate swap contract. The current interest rate swap contract was put in place on March 30, 2011 and terminates on December 31, 2014.

The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and six months ended June 30, 2014.

For the three months ended June 30, 2014 and 2013

Derivatives in ASC 815 Cash Flow Hedging Relationships	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)						Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)
	2014			2013					2014			2013					2014		2013
Interest rate contracts	$	(8	)	$	(7	)		Interest Expense	$	(153	)	$	(181	)		Interest Expense	$	—	$	—
Total	$	(8	)	$	(7	)			$	(153	)	$	(181	)			$	—	$	—

9

For the six months ended June 30, 2014 and 2013

Derivatives in ASC 815 Cash Flow Hedging Relationships	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)						Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)
	2014			2013					2014			2013					2014		2013
Interest rate contracts	$	(31	)	$	(14	)		Interest Expense	$	(312	)	$	(366	)		Interest Expense	$	—	$	(1	)
Total	$	(31	)	$	(14	)			$	(312	)	$	(366	)			$	—	$	(1	)

The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2014, the Company met all covenants in that credit facility.

At June 30, 2014, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $64,057 under the credit facility agreement.

The counterparty to the Company’s interest rate derivative financial instrument is Bank of the West, the Company’s primary bank. Pledged cash collateral is not required under the interest rate swap contract. At June 30, 2014, the Company

did not hold any other derivative financial instruments. As a result, there occurs no offsetting of derivative liabilities in the Company’s condensed consolidated financial statements. The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:

									Gross Amounts Not Offset in the Statement of Financial Position
Description	Gross Amounts of Recognized Liabilities			Gross Amounts Offset in the Statement of Financial Position		Net Amounts of Liabilities Presented in the Statement of Financial Position			Financial Instruments		Cash Collateral Pledged		Net Amount
Derivatives by counterparty:
Bank of the West	$	(283	)	$	—	$	(283	)	$	—	$	—	$	(283	)
Total	$	(283	)	$	—	$	(283	)	$	—	$	—	$	(283	)

9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the June 30, 2014 presentation.

10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the six month period ended June 30, 2014, total comprehensive income consisted of net income attributable to AVD, the change in fair value of interest rate swaps and foreign currency translation adjustments.

11. Stock Based Compensation Expense—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan based on estimated fair values.

Stock Options—During the six months ended June 30, 2014, the Company did not grant any employees options to acquire shares of common stock.

10

Option activity within each plan is as follows:

	Incentive Stock Option Plans			Weighted Average Price Per Share		Exercisable Weighted Average Price Per Share
Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.70
Options exercised, $7.50		(82,650	)		7.50
Balance outstanding, March 31, 2014		478,379		$	7.80	$	7.74
Options exercised, $7.50		(17,500	)		7.50
Balance outstanding, June 30, 2014		460,879		$	7.81	$	7.77

Information relating to stock options at June 30, 2014 summarized by exercise price is as follows:

	Outstanding Weighted Average						Exercisable Weighted Average
Exercise Price Per Share	Shares		Remaining Life (Months)		Exercise Price		Shares		Exercise Price
Incentive Stock Option Plan:
$7.50		434,200		77	$	7.50		434,200	$	7.50
$11.32—$14.75		26,679		74	$	12.90		23,346	$	12.85
		460,879			$	7.81		457,546	$	7.77

The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2014 was as follows:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Months)		Intrinsic Value (thousands)
As of June 30, 2014:
Incentive Stock Option Plans:
Outstanding		460,879	$	7.81		77	$	2,503
Expected to Vest		460,879	$	7.81		77	$	2,503
Exercisable		457,546	$	7.77		77	$	2,503

During the six months ended June 30, 2014 and 2013, the Company recognized stock-based compensation expense, excluding expense associated with modifications, related to stock options of $21 and $423, respectively.

As of June 30, 2014, the Company had no unamortized stock-based compensation expenses related to unvested stock options outstanding. Stock-based compensation expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

11

Restricted Shares—A status summary of non-vested shares as of and for the six months ended June 30, 2014 is presented below:

	Number of Shares			Weighted Average Grant- Date Fair Value
Nonvested shares at December 31, 2013		376,702		$	24.85
Vested		(1,000	)	$	31.83
Forfeited		(1,840	)	$	24.23
Nonvested shares at March 31, 2014		373,862		$	24.83
Granted		240,724		$	14.81
Vested		(23,478	)	$	13.84
Forfeited		—		$	—
Nonvested shares at June 30, 2014		591,108		$	21.19

Restricted stock grants — During the six months ended June 30, 2014, the Company granted a total of 240,724 shares of common stock. Of these, 23,478 shares vest immediately, and the balance will cliff vest after three years of service. The shares granted in 2014 were average fair valued at $14.81 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.

During the six months ended June 30, 2013, the Company granted a total of 154,114 shares of common stock. Of these, 3,000 shares will vest one-third each year on the anniversaries of the employee’s employment date, 8,230 shares vest immediately, and the balance will cliff vest after three years of service. The shares granted in 2013 were average fair valued at $31.22 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.

During the six months ended June 30, 2014 and 2013, the Company recognized stock-based compensation expense related to restricted shares of $1,819 and $1,297, respectively.

As of June 30, 2014, the Company had approximately $7,153 of unamortized stock-based compensation expenses related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.1 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Performance Based Shares—A status summary of non-vested performance based shares as of and for the six months ended June 30, 2014 is presented below:

	Number of Shares		Weighted Average Grant- Date Fair Value
Nonvested shares at December 31, 2013		24,637	$	28.43
Vested		—	$	—
Forfeited		—	$	—
Nonvested shares at March 31, 2014		24,637	$	28.43
Granted		79,270	$	14.23
Vested		—	$	—
Forfeited		—	$	—
Nonvested shares at June 30, 2014		103,907	$	17.60

Performance Based Shares — During the six months ended June 30, 2014, the Company granted a total of 79,270 performance based shares that will cliff vest on May 23, 2017, provided that recipient is continuously employed by the Company during the vesting period. 80% of these performance based shares are based upon financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30% for the period commencing April 1, 2014 and ending December 31, 2016; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement

12

period. The EBIT and net sales goal measures the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The shareholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2014 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.

During the six months ended June 30, 2013, the Company granted a total of 26,942 performance based shares that will cliff vest after three years of service. 80% of these performance based shares are based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015. Both parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.

The performance based shares related to EBIT and net sales were average fair valued at $14.92 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to AVD stock price were average fair valued at $11.47 per share. The fair value was determined by using the Monte Carlo valuation method. The Company is recognizing as expense the value of these shares over the required service period of three years.

During the six months ended June 30, 2014, the Company recognized a reduction in stock-based compensation expense related to performance based shares of $34. During the six months ended June 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of $26.

As of June 30, 2014, the Company had approximately $1,559 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.6 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

12. Legal Proceedings—Summarized below are litigation matters in which there has been material activity or developments during the three month period ended June 30, 2014.

A. DBCP Cases—Delaware

A number of suits have been filed against AMVAC, alleging injury from exposure to the agricultural chemical 1, 2-dibromo-3-chloropropane (“DBCP^®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the United States Environmental Protection Agency (“USEPA”) to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. The USEPA suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product. There are approximately 100 lawsuits, foreign and domestic, filed by former banana workers in which AMVAC has been named as a party. Fifteen of these suits have been filed in the United States (with prayers for unspecified damages) and the remainder has been filed in Nicaragua. All of these actions are in various stages and allege injury from exposure to DBCP, including claims for sterility. Except for the cases described below, there have been no material developments in these matters since the filing of the Company’s Form 10-Q for the period ended March 30, 2014.

In what has been designated as the remaining Hendler-Delaware cases (involving claims for physical injury arising from alleged exposure to DBCP over the course of the late 1960’s through the mid-1980’s on behalf of about 2,700 banana plantation workers from Costa Rica, Ecuador, Guatemala and Panama – more fully described in the Company’s Form 10-K for the period ended December 31, 2013), on May 27, 2014, the district court granted defendant Dole’s motion to dismiss the matter without prejudice on the grounds that the applicable statutes of limitation had expired. In reaching its finding, the court noted that while the Delaware Supreme Court in Blanco had established that Delaware now recognizes the concept of cross-jurisdictional tolling, the factual question as to the tolling of the statute had not been decided by the Blanco court. The court in the Hendler – Delaware cases found that, in fact, the applicable statute of limitations had stopped in 1995. The court left open the possibility that plaintiffs could bring forward evidence that they did not know of their injuries and the causes thereof until a later date, but went on to note that such a showing might be difficult given that many of the symptoms identified by plaintiffs (e.g., vision loss, skin conditions and gastrointestinal problems) are of an obvious nature.

13

B. Other Matters

AMVAC has been named as one of 46 defendants in an action entitled Mark Spence v. A.W. Chesterton Company et al. which was filed on June 16, 2014 with the Circuit Court of Cook County, Illinois as case number 2014L006394 in which plaintiff alleges to have developed mesothelioma from exposure to asbestos-containing products while working as a construction and lawn care laborer in Illinois over the period 1968 to 1990. Among a laundry list of pipe covers, gaskets, roof shingles and construction materials, plaintiff alleges that he was also exposed to unnamed products of AMVAC including “asbestos contaminated fertilizers, herbicides and other horticultural products.” The Company is unaware of having ever sold any product or packaging that incorporated asbestos and believes that this claim has no merit. We plan to defend the matter vigorously. The Company believes that a loss is neither probable nor reasonably estimable and has not established a loss contingency for the matter.

13. Recently Issued Accounting Guidance—In June 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.

In February 2013, FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012. The Company adopted this standard effective January 1, 2013.

14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.

The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of June 30, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:

	Fair Value Measurements Using Input Type
	Level 1		Level 2		Level 3
As of June 30, 2014:
Liability:
Interest rate derivative financial instruments (1)	$	—	$	283	$	—
As of December 31, 2013:
Liability:
Interest rate derivative financial instruments (1)	$	—	$	564	$	—

(1) Includes accrued interest expense

The valuation techniques used to measure the fair value of the derivative financial instruments above in which the counterparties have high credit ratings, were derived from pricing models, such as discounted cash flow techniques, with all significant inputs derived from or corroborated by observable market data. The Company’s discounted cash flow techniques use observable market inputs, such as LIBOR-based yield curves and foreign currency forward rates.

14

15. Accumulated Other Comprehensive Loss—

The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:

	Interest Rate Swap			FX Translation			Total
Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
Other comprehensive loss before reclassifications		(23	)		51			28
Amounts reclassified from AOCI		159			—			159
Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)
Other comprehensive loss before reclassifications		(8	)		92			84
Amounts reclassified from AOCI		153			—			153
Balance, June 30, 2014	$	(59	)	$	(565	)	$	(624	)

16. On March 25, 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, to acquire an ownership position of approximately 29.27%. In February 2014, TyraTech issued 37,391,763 shares and raised approximately £1.87 ($3.1) million. Due to the share issuance, the Company recognized a $256 gain from the dilution of the Company’s ownership position. Following the issuance of these new shares, as of June 30, 2014, the Company’s ownership position in TyraTech was approximately 23.96%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the six months ended June 30, 2014, the Company recognized an operating loss of $396 as a result of the Company’s ownership position in TyraTech.

The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At June 30, 2014, the carrying value of the Company’s investment in TyraTech was $2,561, and the quoted market value of its shareholding was $7,049 based on the London Stock Exchange, Alternative Investment Market (“AIM”).

17. Income Taxes – Income tax expense was $856 for the six months ended June 30, 2014 as compared to $12,941 for the six months ended June 30, 2013. The effective tax rate was 27% in 2014 and 34% in 2013. Income tax benefit was $160 for the three months ended June 30, 2014, and income tax expense was $3,961 for the three months ended June 30, 2013.

The effective tax rate for the three months ended June 30, 2014 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

18. Subsequent event —As of July 18, 2014, AMVAC Chemical Corporation (“AMVAC”), our principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. Under the First Amendment, the Consolidated Funded Debt Ratio has been increased for the third and fourth quarters of 2014 and the first quarter of 2015, and, further, borrowers are permitted to pay cash dividends to shareholders during the first and second quarters of 2015 notwithstanding prior net income levels.

15

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Numbers in thousands)

FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

RESULTS OF OPERATIONS

Quarter Ended June 30:

	2014			2013			Change
Net sales:
Insecticides	$	34,524		$	39,218		$	(4,694	)
Herbicides/soil fumigants/fungicides		13,926			24,699			(10,773	)
Other, including plant growth regulators		8,929			13,228			(4,299	)
Total Crop		57,379			77,145			(19,766	)
Non-crop		10,934			9,616			1,318
	$	68,313		$	86,761		$	(18,448	)
Cost of sales:
Insecticides	$	21,063		$	21,386		$	(323	)
Herbicides/soil fumigants/fungicides		8,936			11,958			(3,022	)
Other, including plant growth regulators		6,089			6,910			(821	)
Total crop		36,088			40,254			(4,166	)
Non-crop		6,165			4,441			1,724
	$	42,253		$	44,695		$	(2,442	)
Gross profit:
Insecticides	$	13,461		$	17,832		$	(4,371	)
Herbicides/soil fumigants/fungicides		4,990			12,741			(7,751	)
Other, including plant growth regulators		2,840			6,318			(3,478	)
Gross profit crop		21,291			36,891			(15,600	)
Gross profit non-crop		4,769			5,175			(406	)
	$	26,060		$	42,066		$	(16,006	)
Gross profit crop		37	%		48	%
Gross profit non-crop		44	%		55	%
Total gross profit		38	%		48	%
	2014			2013			Change
Net sales:
US	$	50,094		$	67,837		$	(17,743	)
International		18,219			18,924			(705	)
	$	68,313		$	86,761		$	(18,448	)

16

Financial performance for the quarter ended June 30, 2014 included net sales of $68,313 which were down approximately 21% from net sales of $86,761 for the second quarter of 2013. Our gross profit performance ended at $26,060 or 38% of net sales as compared $42,066 or 49% of net sales for the comparable quarter last year. The decrease in gross profit resulted largely from elevated levels of unabsorbed factory costs arising from a deliberate slowdown in manufacturing activity in the face of higher inventory levels. Our operating expenses for the period declined by 13% to $25,337 for the three month period ended June 30, 2014, as compared to the same period of the prior year. However, operating expenses increased as a percentage of sales, due primarily to a drop in net sales in the face of substantially fixed costs that support long-term development and growth of the business. For the quarter, we have an income tax benefit of $160, as compared to an income tax expense of $3,961 for the same period of the prior year. Net income attributable to AVD ended at $145, as compared to $8,386 in the prior year.

With respect to sales performance by category, net sales for our crop business were down by approximately 26%, while net sales for non-crop products were up by about 14% for the comparable period of the prior year. From a geographic perspective, our domestic sales were down 26% and our international sales were down 4% over the comparable quarter in 2013. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Second quarter financial performance was significantly influenced by reduced re-stocking procurement, as distributors/retailers/corn growers in the Midwest United States worked through surplus inventories that had been carried over from the 2013 spring planting season. As we reported a year ago, continuous rainfall in this region created considerable difficulties in the planting of the 2013 corn crop. With several million acres of unplanted muddy fields and extensive planting delays, many crop protection inputs went unused in 2013. While wet conditions did not adversely affect AVD’s 2013 sales of either our corn insecticides or corn herbicide for that reporting period, they did affect the “on-the-ground” use of these products, leaving higher than normal stocks in customers’ inventories for the 2014 season. As these products have been used during 2014 planting, a much lower-than-normal level of restocking purchases has resulted in reduced 2014 sales of these corn related products.

Net sales of our insecticide group were down about 12%, to $34,524 as compared to $39,218 during the second quarter of 2013. Within insecticides, net sales of our granular soil insecticides (“GSIs”) were down approximately 17%, as compared to the comparable quarter in 2013, driven by the reduced corn soil insecticides replenishment activity referred to above. Partially offsetting this drop was a 3% increase in our non-corn insecticide products primarily driven by strong sales of our Bidrin product for cotton due to heavier insect pressure in this year’s cotton crop.

Within the group of herbicides/fungicides/fumigants, net sales for the second quarter of 2014 decreased by approximately 44% to $13,926 from $24,699 in the same period of 2013. Net sales of our herbicide products declined significantly after the strong sales of our post-emergent corn herbicide, Impact in the second quarter of 2013. As in the case of corn insecticides discussed above, inventories of Impact in the distribution channel carried over from the prior year and thereby reduced current year sales. Our fumigant sales were about 2% higher this year despite some localized irrigation restrictions in California.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales dropped by about 32%, as compared to those in the second quarter of 2013. This decrease was due largely to a 31% decline in quarterly sales of our cotton harvest defoliant, Folex, driven primarily by timing of demand. With a modest increase in cotton acreage over the prior year, we would expect additional sales in the upcoming third quarter of 2014 closer to the time of use of the product during the autumn cotton harvest.

Our non-crop sales ended the second quarter of 2014 at $10,934 which was a 14% increase over net sales of $9,616 for the same period of the prior year. This increase resulted from strong sales of our mosquito adulticide Dibrom^®, improved sales of our Envance product line, which, although modest, increased almost twofold in comparison to the same period of the prior year, and a 45% increase in our pharmaceutical products.

Our cost of sales for the second quarter of 2014 was $42,253 or 62% of net sales. This compared to $44,695 or 52% of net sales for 2013. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. The two major cost components are raw materials (including subcontract costs) and factory operating costs. During the quarter, our raw material costs decreased by 21%, which was consistent with the reduction in sales. Our factory expenses were down by approximately 8% year-over-year, as we focused on reducing costs. However, in light of higher-than-normal inventory levels for certain corn products both in the distribution channel and at the Company, we made the decision to reduce output and, by implication, manufacturing activity. With materially lower plant activity and slightly lower plant costs, we incurred an increase in unabsorbed factory expenses as compared to the comparable quarter. In fact, approximately one third of the reduction in gross profit is attributed to increased unabsorbed factory expenses. This translates to a 10% drop in gross margin. The balance arose from reduced domestic sales primarily in our corn market, and, at the same time, proportionately increased international sales (which attract lower gross profit levels). As a result, our gross profit ended at 38% of sales, as compared to 48% in the same period of the prior year.

17

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses decreased by $3,832 to $25,337 for the three months ended June 30, 2014 as compared to the same period in 2013. The differences in operating expenses by department are as follows:

	2014		2013		Change
Selling	$	8,805	$	8,451	$	354
General and administrative		6,068		9,958		(3,890	)
Research, product development and regulatory		5,040		5,068		(28	)
Freight, delivery and warehousing		5,424		5,692		(268	)
	$	25,337	$	29,169	$	(3,832	)

• Selling expenses increased by approximately 4% over the same quarter of the prior year. The main drivers for increased overall expenses were costs associated with our expanded international sales and marketing team and increased advertising and promotional activities driving our brands.

• General and administrative expenses decreased by 39% to $6,068 as compared to $9,958 for the same period of the prior year. The main drivers for the decrease are primarily related to reduced incentive compensation, lower legal costs and lower third party consulting costs associated with the creation of our international subsidiary structure in 2013.

• Research, product development costs and regulatory expenses were essentially flat compared to the same period of the prior year. Within this result, our spending on regulatory compliance was down and this was offset by increased spending on product and business development.

• Freight, delivery and warehousing costs decreased by about 5%, which was driven by volume and by mix. We also incurred higher costs related to our warehousing activity driven by elevated inventory levels. As a percentage of sales, freight ended at 7.9% of sales for the three months ended June 30, 2014 as compared to 6.6% for the same period of the prior year.

Interest costs, net of capitalized interest, were $844 in the three months ended June 30, 2014, as compared to $670 in the same period of 2013. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

	Q2 2014								Q2 2013
	Average Debt		Interest Expense			Interest Rate			Average Debt		Interest Expense			Interest Rate
Term loan	$	—	$	—			—		$	42,054	$	407			3.9	%
Working capital revolver		111,779		684			2.4	%		33,725		189			2.2	%
Average		111,779		684			2.4	%		75,779		596			3.1	%
Other notes payable		170		1			2.4	%		242		2			3.3	%
Interest income		—		(3	)		—			—		—			—
Capitalized interest		—		(13	)		—			—		(31	)		—
Amortization of deferred loan fees		—		58			—			—		38			—
Amortization of other deferred liabilities		—		105			—			—		56			—
Other interest expense		—		12			—			—		9			—
Adjusted average indebtedness	$	111,949	$	844			3.0	%	$	76,021	$	670			3.5	%

The Company’s average overall debt for the three months ended June 30, 2014 was $111,949 as compared to $76,021 for the three months ended June 30, 2013. During the quarter we increased our usage of revolving debt to fund elevated levels of working capital. As can be seen from the table above, our effective bank interest rate was 2.4% for the three months ended as compared to 3.1% in 2013. This is driven by the New Credit Agreement and the reduced proportion of our debt covered by the interest rate swap contract.

18

Income tax expense decreased by $4,121 to end at $(160) for the three months ended June 30, 2014 as compared to $3,961 for the comparable period in 2013. The income tax benefit for the quarter is the result of lower projected domestic earnings. The decreased annual domestic projection impacts the Company’s forecast for the purpose of estimating its quarterly income tax rate. The effective rate for the comparable period of 2013 was 32%.

The effective tax rate for the three months ended June 30, 2014 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the three months ended June 30, 2014, we recognized a loss of $68 on our investment in TyraTech. No income or loss was recognized during the three months ended June 30, 2013.

Non-controlling interest for the three months ended June 30, 2014 increased to $174 as compared to $120 for the three months ended June 30, 2013. Non-controlling interest represents the share of net loss that is attributable to TyraTech, the minority shareholder, of our majority owned subsidiary, Envance.

Our overall net income for the second quarter of 2014 was $145 or $0.01 per diluted share ($0.01 per share—basic) as compared to $8,386 or $0.29 per diluted share ($0.29 per share—basic) in the same quarter of 2013.

Six Months Ended June 30:

	2014			2013			Change
Net sales:
Insecticides	$	80,961		$	118,085		$	(37,124	)
Herbicides/soil fumigants/fungicides		36,857			57,685			(20,828	)
Other, including plant growth regulators		12,736			16,919			(4,183	)
Total crop		130,554			192,689			(62,135	)
Non-crop		18,854			15,609			3,245
	$	149,408		$	208,298		$	(58,890	)
Cost of goods sold:
Insecticides	$	51,651		$	65,677		$	(14,026	)
Herbicides/soil fumigants/fungicides		22,406			29,948			(7,542	)
Other, including plant growth regulators		9,524			8,300			1,224
Total crop		83,581			103,925			(20,344	)
Non-crop		10,862			8,526			2,336
	$	94,443		$	112,451		$	(18,008	)
Gross profit:
Insecticides	$	29,310		$	52,408		$	(23,098	)
Herbicides/soil fumigants/fungicides		14,451			27,737			(13,286	)
Other, including plant growth regulators		3,212			8,619			(5,407	)
Gross profit crop		46,973			88,764			(41,791	)
Gross profit non-crop		7,992			7,083			909
	$	54,965		$	95,847		$	(40,882	)
Gross profit crop		36	%		46	%
Gross profit non-crop		42	%		46	%
Total gross profit		37	%		46	%
	2014			2013			Change
Net sales:
US	$	108,050		$	170,942		$	(62,892	)
International		41,358			37,356			4,002
	$	149,408		$	208,298		$	(58,890	)

Overall financial performance including net sales and net income for the six month period ended June 30, 2014 showed a decline as compared to the same period in 2013. Net sales for the period were down approximately 28% to $149,408

19

compared to $208,298 for the first half of 2013. Our gross profit performance ended at $54,965 or 37% of net sales, as compared to $95,847 or 46% of net sales for the comparable prior period. Our operating expenses reduced by 11% and ended at $50,280 for the period ended June 30, 2014, as compared to $56,798 for comparable period of the prior year. Expressed as a percentage of sales, operating expenses increased to 34% of sales as compared to 27% in 2013; this increase resulted from a drop in net sales and the incurrence of substantially fixed costs which have been put in place to support long-term development and growth of the business. Notwithstanding the substantially fixed nature of these costs, we are working hard to control all discretionary spending in an effort to reduce expenses to 90% or less than expenses incurred in 2013. Our tax rate improved to 27% for the six month period as compared to 34% recorded in 2013. This improved tax rate was driven primarily by the increased proportion of international versus domestic taxable income. Overall net income attributable to AVD ended down at $2,304 for the six month period ended June 30, 2014, as compared to $25,301 for the same period of the prior year.

With respect to specific categories, net sales for our crop business were down by approximately 32%, while net sales for non-crop products were up by about 21% from the comparable period of the prior year. Our international sales also grew by 11%, as compared to the performance recorded in the same period of 2013. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Over the course of the first half of 2014, the Company experienced soft demand for many of its corn products. This was primarily due to below normal re-stocking procurement by the Midwest channel of distribution as it worked through surplus inventories of products left in the distribution channel at the end of the 2013 planting season.

Net sales of our insecticides for the six months ended June 30, 2014 were down about 31% to $80,961, as compared to $118,085 during the first half of 2013. Within this category, net sales of our granular soil insecticides (“GSIs”) were down approximately 36% over that of the comparable period in 2013. Our primary corn soil insecticides Aztec, SmartChoice, and Force all experienced declines because of the Midwest corn purchasing patterns described above. However, our Thimet sales increased on peanut acres and our Mocap and Nemacur products increased in the international arena. Net sales of our non-GSI insecticides were approximately 18% higher during the first half of 2014 as compared to the same period of the prior year, largely because sales of our foliar insecticide Bidrin increased in cotton.

Within the group of herbicides/fungicides/fumigants, net sales for the first half of 2014 were 36% lower as compared to the first half of 2013. Net sales of our primary corn herbicide Impact declined – again as a result of 2013 inventory carryover, while our soil fumigants and fungicides increase modestly for the half year.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales dropped by about 25% as compared to those in the first half of 2013. Contributing to this decrease were lower sales of our cotton harvest aid, Folex, and a slight decline in toll manufacturing revenues.

Our non-crop sales for the first half of 2014 were $18,854, up 21% from $15,609 for the same period of the prior year. Sales of both our mosquito adulticide Dibrom^® and our Pest Strip business contributed to the year on year improvement along with an increase in year-over-year pharmaceutical sales.

Our cost of sales for the first six months of 2014 was $94,443 or 63% of net sales, compared to $112,451 or 54% of net sales for 2013. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. The two major cost components are raw materials (including sub contract costs) and factory operating costs. During the six month period, our raw material costs decreased by 27%, which is broadly consistent with the reduction in our reported net sales. Our factory expenses were down by approximately 5% year-over-year as we focused on reducing costs. However, in light of higher-than-normal inventory levels for certain corn products both in the distribution channel and at the Company, we made the decision to reduce output and, by implication, manufacturing activity. With materially lower plant activity and slightly lower plant costs, we incurred an increase in unabsorbed factory expenses as compared to the comparable quarter. In fact, approximately one quarter of the reduction in gross profit is attributed to increased unabsorbed factory expenses. This translates to an 8% drop in gross margin for the six month period. The balance arose from proportionately increased international sales which attracts lower gross profit levels and to a lesser extent from the change in product mix in our U.S. markets as compared to the same period of the prior year. As a result, our gross profit ended at 37% of sales, as compared to 46% in the same period of the prior year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

20

Operating expenses decreased by $6,518 to $50,280 for the six months ended June 30, 2014, as compared to the same period in 2013. The differences in operating expenses by department are as follows:

	2014		2013		Change
Selling	$	16,976	$	15,682	$	1,294
General and administrative		12,542		20,171		(7,629	)
Research, product development and regulatory		9,773		9,612		161
Freight, delivery and warehousing		10,989		11,333		(344	)
	$	50,280	$	56,798	$	(6,518	)

• Selling expenses for the period increased by about 8% over the comparable period. The main drivers for increased overall expenses were costs associated with our expanded domestic and international sales and marketing team, increased advertising and promotional activities driving our brands.

• General and administrative expenses decreased by about 38% over the same period of 2013. The main drivers are reduced incentive compensation offset somewhat by increased costs related to the continual development of our support organization, reduced legal bills related to a data compensation matter that concluded last year and lower expenses related to consulting costs incurred in the prior year, as we established our international structure.

• Research, product development costs and regulatory expenses were essentially flat, with reduced expenditures in product defense offset by increased costs incurred in our formulation chemistry activities and business development initiatives.

• Freight, delivery and warehousing costs for the six months ended June 30, 2014 were $10,989 or 7.4% of sales as compared to $11,333 or 5.4% of sales for the same period in 2013. This reflects reduced sales overall, with a higher proportion of higher cost international shipments. We are also incurring higher overall costs associated with elevated levels of inventory.

Interest costs, net of capitalized interest, were $1,457 in the six months of 2014 as compared to $1,023 in the same period of 2013. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

	Six months ended June 30, 2014								Six months ended June 30, 2013
	Average Debt		Interest Expense			Interest Rate			Average Debt		Interest Expense			Interest Rate
Term loan	$	—	$	—			—		$	47,023	$	880			3.7	%
Working capital revolver		93,728		1,173			2.5	%		16,956		189			2.2	%
Average		93,728		1,173			2.5	%		63,979		1,069			3.3	%
Other notes payable		178		3			3.4	%		327		4			2.4	%
Interest income		—		(3	)		—			—		—			—
Capitalized interest		—		(31	)		—			—		(225	)		—
Amortization of deferred loan fees		—		117			—			—		70			—
Amortization of other deferred liabilities		—		174			—			—		86			—
Other interest expense		—		24			—			—		19			—
Adjusted average indebtedness	$	93,906	$	1,457			3.1	%	$	64,306	$	1,023			3.2	%

The Company’s average overall debt for the six months ended June 30, 2014 was $93,906 as compared to $64,306 for the six months ended June 30, 2013. During the period, we increased our usage of revolving debt to fund elevated levels of working capital as demand has been slower than anticipated, and as a result, the inventory overhang continues to drive working capital. As can be seen from the table above, our effective bank interest rate was 2.5% for the six months ended June 30, 2014 as compared to 3.3% for the same period in 2013. This is driven by the new credit facility agreement and the reduced proportion of our debt covered by the interest rate swap contract.

Income tax expense decreased by $12,085 to end at $856 for the six months ended June 30, 2014 as compared to $12,941 for the comparable period in 2013. The effective tax rate for the period was 27% as compared to 34% in the same period of the prior year. The decrease in the effective tax rate is primarily due to lower projections of the Company’s forecasted domestic earnings.

21

The effective tax rate for the six months ended June 30, 2014 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the six months ended June 30, 2014, we recognized a loss of $396 on our investment in TyraTech. No income or loss was recognized during the six months ended June 30, 2013. The loss is exclusive of a gain of $256 related to the sale by TyraTech of additional stock.

Non-controlling interest for the six months ended June 30, 2014 increased to $328 as compared to $216 for the six months ended June 30, 2013. Non-controlling interest represents the share of net loss that is attributable to TyraTech, the minority shareholder, of our majority owned subsidiary, Envance.

Our overall net income for the first six months of 2014 was $2,304 or $0.08 per diluted share ($0.08 per share—basic) as compared to $25,301 or $0.88 per diluted share ($0.89 per share—basic) in the same period of 2013.

LIQUIDITY AND CAPITAL RESOURCES

The Company used $29,059 of cash in operating activities during the six months ended June 30, 2014. This compared with generating $20,045 in the same period of last year. Net income of $1,976, the sum of non-cash depreciation, amortization of intangibles, other assets and discounted future liabilities equaled $11,198 and stock based compensation expense and other non-cash items of $1,684 provided a net cash inflow $14,858 compared to $36,124 for the same period last year.

During the six months ended June 30, 2014, the Company has recorded significantly lower sales in its key corn soil insecticides and herbicides, in comparison to the same period of the prior year. Our receivables ended the quarter slightly higher than at the end of the second quarter of the prior year. In 2014 we have a slightly higher proportion of international receivable accounts having repayment terms that are, on average, longer than our domestic terms.

Our inventories have increased $35,410 during the six month period due to slow sales, the arrival of long lead time raw material supplies, offset by reduced factory output. As of the balance sheet date, June 30, 2014, we believe our inventories are valued at lower of cost or market.

During the six months ended June 30, 2014, deferred revenues reduced by $2,276, as compared to $20,149 for the same period of the prior year. The scale of the reduction reflects the amount of early payments made by customers during the fourth quarter of both 2013 and 2012.

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30^th each year. During the six months ended June 30, 2014, the Company made accruals in the amount of $30,355. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. However, there are some programs that are paid more frequently or that have different settlement dates that reflect particular growing seasons. During the first six months of 2014, the Company made payments in the amount of $9,626. Payments are not generally significant in the second and third quarters of each financial year. During the six months ended June 30, 2013, the Company accrued $65,842 and made payments in the amount of $9,669.

Finally, our prepaid and other assets increased by $5,069 as annual contracts are paid at the beginning of the year. Furthermore, accounts payable decreased by $16,521 as purchases continue to decrease in response to actions to reduce our inventory.

The Company is working to manage its capital spending very closely during this slow trading period and utilized $3,954 during the six months ended June 30, 2014, compared to utilizing $8,360 during the same period of 2013. This is primarily driven by capital spending in our factories. During the six months ended June 30, 2013, the Company made a $3,687 investment in TyraTech Inc. There was no similar investment made in 2014.

Financing activities provided $30,432 during the six months ended June 30, 2014, compared to utilizing $14,034 in the same period of the prior year. This included significant draws of $34,450 against our senior credit facility. During the period we have made immaterial scheduled deferred payments related to product acquisitions. Further, the Company made dividend payments in the amount of $2,836 and, during the first three months of 2014, utilized $1,531 repurchasing shares of our common stock in accordance with our repurchase policy aimed at offsetting dilution caused by incentive compensation. This repurchase activity has been temporarily placed on hold as the Company seeks to control cash flow. Finally, the Company received $1,458 from the exercise of stock options and the sale of common stock under its Employee Stock Purchase Plan (including associated tax benefits of $262) as compared to $584 for the same period of last year.

22

The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the balance sheets at June 30, 2014 and December 31, 2013. These are summarized in the following table:

Indebtedness	June 30, 2014						December 31, 2013
$000’s	Long- term		Short- term		Total		Long- term		Short- term		Total
Revolving line of credit	$	86,000	$	—	$	86,000	$	51,550	$	—	$	51,550
Notes payable		91		70		161		126		69		195
Total Indebtedness	$	86,091	$	70	$	86,161	$	51,676	$	69	$	51,745

The Company has three key covenants under its senior credit facility. The covenants are as follows: The Company must (1) maintain its borrowings below a certain consolidated funded debt ratio, (2) limit its annual spending on the acquisition of fixed asset capital additions, and (3) maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2014, the Company was in compliance with all covenants. On July 18, 2014, the senior credit facility agreement was amended. See Note 18 of the Notes to Condensed Consolidated Financial Statements.

At June 30, 2014, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $64,057.

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

23

RECENTLY ISSUED ACCOUNTING GUIDANCE

In June 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.

In February 2013, FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012. The Company adopted this standard effective January 1, 2013.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements for inclusion in the AVD published financial statements. In the Company’s condensed consolidated Form 10-K for the financial year ended December 31, 2013, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. All the policies listed in the Company’s Form 10-K for the year ended December 31, 2013 remain valid and are hereby incorporated by reference.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2013. The Company uses derivative financial instruments for trading purposes to protect trading performance from exchange rate fluctuations on material contracts.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

Item 4. CONTROLS AND PROCEDURES

As of June 30, 2014, the Company has established a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in its filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2014, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

24

PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

Item 1. Legal Proceedings

Legal Proceedings—Summarized below are litigation matters in which there has been material activity or developments since the filing of the Company’s Form 10-Q for the period ended March 31, 2014.

A. DBCP Cases—Delaware

A number of suits have been filed against AMVAC, alleging injury from exposure to the agricultural chemical 1, 2-dibromo-3-chloropropane (“DBCP^®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the United States Environmental Protection Agency (“USEPA”) to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. The USEPA suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product. There are approximately 100 lawsuits, foreign and domestic, filed by former banana workers in which AMVAC has been named as a party. Fifteen of these suits have been filed in the United States (with prayers for unspecified damages) and the remainder has been filed in Nicaragua. All of these actions are in various stages and allege injury from exposure to DBCP, including claims for sterility. Except for the cases described below, there have been no material developments in these matters since the filing of the Company’s Form 10-Q for the period ended March 30, 2014.

In what has been designated as the remaining Hendler-Delaware cases (involving claims for physical injury arising from alleged exposure to DBCP over the course of the late 1960’s through the mid-1980’s on behalf of about 2,700 banana plantation workers from Costa Rica, Ecuador, Guatemala and Panama – more fully described in the Company’s Form 10-K for the period ended December 31, 2013), on May 27, 2014, the district court granted defendant Dole’s motion to dismiss the matter without prejudice on the grounds that the applicable statutes of limitation had expired. In reaching its finding, the court noted that while the Delaware Supreme Court in Blanco had established that Delaware now recognizes the concept of cross-jurisdictional tolling, the factual question as to the tolling of the statute had not been decided by the Blanco court. The court in the Hendler – Delaware cases found that, in fact, the applicable statute of limitations had stopped in 1995. The court left open the possibility that plaintiffs could bring forward evidence that they did not know of their injuries and the causes thereof until a later date, but went on to note that such a showing might be difficult given that many of the symptoms identified by plaintiffs (e.g., vision loss, skin conditions and gastrointestinal problems) are of an obvious nature.

B. Other Matters

AMVAC has been named as one of 46 defendants in an action entitled Mark Spence v. A.W. Chesterton Company et al. which was filed on June 16, 2014 with the Circuit Court of Cook County, Illinois as case number 2014L006394 in which plaintiff alleges to have developed mesothelioma from exposure to asbestos-containing products while working as a construction and lawn care laborer in Illinois over the period 1968 to 1990. Among a laundry list of pipe covers, gaskets, roof shingles and construction materials, plaintiff alleges that he was also exposed to unnamed products of AMVAC including “asbestos contaminated fertilizers, herbicides and other horticultural products.” The company is unaware of having ever sold any product or packaging that incorporated asbestos and believes that this claim has no merit. We plan to defend the matter vigorously. The company believes that a loss is neither probable nor reasonably estimable and has not established a loss contingency for the matter.

The balance sheet at June 30, 2014 includes loss contingencies relating to certain legal proceedings more fully described in Item 3 of the Company’s Form 10-K for the period ended December 31, 2013 (the 2013 10-K). To the extent that there has been no material change in any such proceeding or in the contingency related thereto since the filing of the 2013 10-K, no additional disclosure about such matter is included in this Form 10-Q.

25

Item 1A. Risk Factors

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in AVD’s Report on Form 10-K for the fiscal year ended December 31, 2013, filed on February 28, 2014. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors other than as follows:

Higher than normal levels of inventory may lead to continued, decreased profitability. The Company manufactures more than half of its products, including the majority of its corn soil insecticides which, in years of strong financial performance, have comprised a significant portion of our consolidated net sales. Reduced use of the Company’s corn products in 2013 and reduced sales of those products in 2014 have led to higher-than-normal inventory levels at the Company. In the interest of reducing excess inventory, the Company has decreased manufacturing activity at its facilities; this has had the effect of decreasing the Company’s absorbed manufacturing costs and thereby the Company’s profitability. If demand for these products does not increase, then the attendant under absorption of manufacturing costs will continue to affect the Company’s profitability adversely. There is no guarantee that the Company will be able to reduce its inventory levels materially, increase plant activity or return to greater profitability.

Corn commodity prices may affect the Company’s financial performance. The Company’s corn products are an important element of its overall financial performance. To the extent that corn commodity prices decline and/or the ratio of other crop prices (such as soybeans) to corn prices increases, growers may either cut back on crop inputs, plant less corn, plant other crops in lieu of corn or plant nothing. Any one or all of these decisions may have the effect of reducing the sales of the Company’s corn products and, consequently, its financial performance.

26

Item 6. Exhibits

Exhibits required to be filed by Item 601 of Regulation S-K:

Exhibit No.	Description
10.1	Form of AVD Amended and Restated Stock Incentive Plan Performance-Based Restricted Stock Units Awards Agreement dated May 23, 2014
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.
32.1	Certification Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.
101	The following materials from AVD’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations and Comprehensive Income; (iii) Condensed Consolidated Statements of Cash Flows; (iv) Condensed Consolidated Statements of Stockholders’ Equity; and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

27

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMERICAN VANGUARD CORPORATION
Dated: July 31, 2014	By:	/S/    ERIC G. WINTEMUTE
		Eric G. Wintemute Chief Executive Officer and Chairman of the Board
Dated: July 31, 2014	By:	/S/    DAVID T. JOHNSON
		David T. Johnson Chief Financial Officer & Principal Accounting Officer

28

EX-10.1

Exhibit 10.1

AMERICAN VANGUARD CORPORATION

AMENDED AND RESTATED STOCK INCENTIVE PLAN

PERFORMANCE-BASED RESTRICTED STOCK UNITS AWARD AGREEMENT

May 23, 2014

American Vanguard Corporation, a Delaware Corporation, (“Company”) hereby grants to                      (“Grantee”), a Participant in the American Vanguard Corporation Amended and Restated Stock Incentive Plan, as amended from time-to-time (“Plan”), a Performance-Based Restricted Stock Units Award (“Award”) for Units (“Units”) representing shares of the common stock of the Company (“Stock”). This agreement to grant Stock Units (“Award Agreement” or “Grant Agreement”) is made effective as of the 23rd day of May, 2014 (“Grant Date”). If Grantee is a Covered Employee, this Award is designated as a “Performance Compensation Award” and as such is granted pursuant to Article 11 of the Plan.

RECITALS

A. The Board of Directors of the Company (“Board”) has adopted the Plan as an incentive to retain employees, officers, and non-employee Directors of, and Consultants to, the Company and to enhance the ability of the Company to attract, retain and motivate individuals upon whose judgment, interest and special effort the successful conduct of the Company’s operation is largely dependent.

B. Under the Plan, the Board has delegated its authority to administer the Plan to the Compensation Committee of the Board (“Committee”).

C. The Committee has approved the granting of Units to the Grantee pursuant to the Plan to provide an incentive to the Grantee to focus on the long-term growth of the Company.

D. The Committee, which consists of three outside directors, has established the performance goals set forth herein.

E. To the extent not specifically defined herein or in the Grantee’s employment agreement or comparable agreement, as amended from time to time (“Employment Agreement”), each of the capitalized terms used in this Award Agreement shall have the meaning set forth in the Plan unless a contrary meaning is set forth in the Employment Agreement.

In consideration of the mutual covenants and conditions hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Grantee agree as follows:

1. Grant of Units. The Company hereby grants to the Grantee a Performance-Based Restricted Stock Units Award for              Units (“Granted Units”), representing the right to receive payment of the same number of shares of Stock, subject to the terms and conditions of this Award Agreement and the provisions of the Plan, which terms are incorporated herein by reference.

2. Earning Units and Related Information.

2.1 Earning Units. Subject to the terms and conditions set forth in this Grant Agreement, the Grantee shall be entitled to receive payment for the number of Units earned by the Grantee over the period that begins on April 1, 2014 and ends on December 31, 2016 (“Performance Measurement Period”).

2.2 Performance Goals: There shall be three performance goals, weighted as follows for purposes of determining the potential incentive units for each participant: an EBIT (earnings before income tax) goal weighted at fifty percent (50%), a Net Sales goal weighted at thirty (30%), and a Total Shareholder Return goal weighted at twenty percent (20%).

2.3 EBIT Goal. The EBIT Goal shall mean the relative growth of the Company’s EBIT (earnings before income taxes) for the Performance Measurement Period (as reported in the financial statements included in the Company’s Forms 10-Q and 10-K) as compared to the median growth of EBIT (computed in terms of compound annual growth) of a peer group (namely, Syngenta, Bayer, BASF, Dow, Monsanto, DuPont, MAI, Nufarm, FMC, Cheminova, United Phosphorus, Chemtura and Isagro, collectively, the “AgPeers Group”). The Company’s reported EBIT for the Performance Measurement Period, for purposes of determining performance goal attainment, shall be adjusted to factor out the effect of the adoption of any new accounting standards or other changes in accounting principles.

2.4 Net Sales Goal: The Net Sales Goal shall mean the relative growth of the Company’s net sales for the Performance Measurement Period (as reported in the financial statements included in the Company’s Forms 10-Q and 10-K) as compared to the median growth of net sales (computed in terms of compound annual growth) for the AgPeers Group. The Company’s reported net sales for the Performance Measurement Period, for purposes of determining performance goal attainment, shall be adjusted to factor out the effect of the adoption of any new accounting standards or other changes in accounting principles.

2.5 Total Shareholder Return Goal: The Total Shareholder Return Goal shall mean the relative growth of the fair market value of the Company’s stock price over the course of the Performance Measurement Period as compared to that of (x) the Russell 2000 Index (“R2000 TSR”) and (y) the median fair market value of the common stock of the comparator companies identified in the Corporation’s 2014 Proxy Statement (“Comparator Group TSR”).

2.6 Calculation of Units Earned. The number of Units earned hereunder shall equal the sum of:

(a) the product of ((number of Granted Units) x (EBIT Performance Factor) x (0.5)) plus

(b) the product of ((number of Granted Units) x (Net Sales Performance Factor) x (0.3)) plus

(c) the product of ((number of Granted Units) x (TSR Performance Factor for R2000 TSR) x (0.1)) plus

(d) the product of ((number of Granted Units) x (TSR Performance Factor for Comparator Group TSR) x (0.1)).

2

2.7 Performance Factors – EBIT and Net Sales Goals. A performance factor (“Performance Factor”) for Units based on each of the EBIT and Net Sales Goals shall be calculated based upon the table set forth below, it being understood that the 100% Goal for both EBIT and Net Sales shall be the median growth for the AgPeers group for each measure:

Table 1 - PERFORMANCE FACTORS – EBIT & Net Sales

% Goal Achieved	% Target Payout1
³125%	200%
117.5%-124.9%	150%
110%-117.4%	125%
100%	100%
80%	50%
<80%	0%

Table 2 - PERFORMANCE FACTORS – TSR Goal

% Goal Achieved	% Target Payout2
³80thpercentile	200%
60th percentile	150%
50th percentile	100%
40th percentile	75%
30th percentile	50%
<30th percentile	0%

Note: Tables 1 and 2 present performance factors where the peers’ median is a positive number. In the event that the peers’ median is negative, and the Company’s performance is also negative, the % Target Payout column will be the inverse of that presented above; thus, for example, with respect to EBIT, the maximum target payout (200%) will apply where the Company achieves 80% or less than the median, the target payout (100%) will apply where the Company achieves the median, and the minimum target payout (50%) will apply where the Company achieves 125% of the median (and 0% if the Company achieves more than 125% of the median). In the event that the peers’ median is negative and the Company’s performance is positive, then the award shall be the maximum payout amount, subject to reduction by the Committee in its discretion.

¹  For performance between 80% and 109.9% of target, the payout percentage is interpolated on a linear basis between points on the “% Goal Achieved” scale.

²  For performance between 30^th%ile and 80^th%ile, the payout percentage is interpolated on a linear basis between points on the “% Goal Achieved” scale.

3

Any Units that are unearned as of the end of the Performance Measurement Period will be forfeited. The number of earned Units that will become vested shall be determined pursuant to paragraph 3 below. Whether the Performance Goals for the Performance Measurement Period have been achieved shall be determined by the Company or Committee, as applicable, pursuant to paragraph 2.8 below.

2.8 Final Determination of Performance Goals Attained. The Company, or the Committee with respect to grants to employees who are Covered Employees, shall be responsible for determining in good faith whether, and to what extent, the Performance Goals set forth in this Grant Agreement have been achieved. The Company, or the Committee, as applicable, may reasonably rely on information from, and representations by, individuals within the Company in making such determination and when made such determination shall be final and binding on the Grantee. No payment shall be made hereunder until the Committee has determined that the performance goals and any other material terms have been satisfied.

3. Vesting of Earned Units. Subject to paragraph 4 below, the Units earned pursuant to paragraph 2.1 shall vest in their entirety on the third anniversary of the date of award, that is, on May 23, 2017.

4. Termination of Employment.

4.1 General. Subject to the provisions of paragraph 4.2 below, (a) if the Company terminates Grantee’s employment without Cause or Grantee’s employment is terminated due to death or disability prior to the Vesting Date, then Units shall vest on a pro-rated basis corresponding with Grantee’s actual service during the Performance Period; and (b) if Company terminates Grantee’s employment for Cause, or Grantee terminates employment with the Company voluntarily, any unvested Units will be canceled and forfeited as of the date of Grantee’s termination of employment. In other words, except as otherwise expressly provided to the contrary in paragraphs 4.1 and 4.2, Grantee must be continuously employed by the Company through the Vesting Date in order to receive any payment with respect to the Units that are scheduled to vest on such Vesting Date.

4.2 Change in Control. In the event the Company terminates the Grantee’s employment without Cause (including, if applicable, a termination for Good Reason as defined in the Grantee’s Employment Agreement or similar document) within two (2) years following a Change in Control, then all Units earned pursuant to paragraph 2.1 but unvested shall become immediately vested. The Vesting Date for any such earned Units that vest pursuant to this paragraph 4.2 shall be the date of the Grantee’s termination of employment.

5. Time and Form of Payment. Subject to the provisions of this Award Agreement and the Plan, as Units vest on the Vesting Dates set forth in paragraph 3, 4.1 or 4.2, as the case may be, the Company will deliver to the Grantee the same number of whole shares of Stock, rounded up or down. Subject to paragraph 21, the Company shall deliver the vested shares (if any) within thirty (30) days of the applicable Vesting Date.

4

6. Nontransferability. The Units granted by this Grant Agreement shall not be transferable by the Grantee or any other person claiming through the Grantee, either voluntarily or involuntarily, except by will or the laws of descent and distribution or as otherwise provided under Article 13 of the Plan.

7. Adjustments. In the event of a stock dividend or in the event the Stock shall be changed into or exchanged for a different number or class of shares of stock of the Company or of another corporation, whether through reorganization, recapitalization, stock split-up, combination of shares, merger or consolidation, there shall be substituted for each such remaining share of Stock then subject to this Grant Agreement the number and class of shares of stock into which each outstanding share of Stock shall be so exchanged, all as set forth in Section 5.3 of the Plan.

8. Delivery of Shares. No shares of Stock shall be delivered under this Award Agreement until: (i) the Units vest pursuant to paragraph 3, 4.1 or 4.2 above, as the case may be; (ii) approval of any governmental authority required in connection with the Award Agreement, or the issuance of shares thereunder, has been received by the Company; (iii) if required by the Committee, the Grantee has delivered to the Company documentation (in form and content acceptable to the Company in its sole and absolute discretion) to assist the Company in concluding that the issuance to the Grantee of any share of Stock under this Grant Agreement would not violate the Securities Act of 1933 or any other applicable federal or state securities laws or regulations; (iv) the Grantee has complied with paragraph 14 below of this Award Agreement in order for the proper provision for required tax withholdings to be made; and (v) the Grantee has executed and returned this Grant Agreement to the Company (which, in the case of a Grant Agreement provided to the Grantee in electronic format, requires that the Grantee click the “ACCEPT” button). This Grant Agreement must be executed by Grantee no later than, the earlier of (i) three (3) months from the Grant Date; or (ii) the date preceding the first Vesting Date described in paragraph 3 of this Grant Agreement.

9. Securities Act. The Company shall not be required to deliver any shares of Stock pursuant to the vesting of Units if, in the opinion of counsel for the Company, such issuance would violate the Securities Act of 1933 or any other applicable federal or state securities laws or regulations.

10. Voting and Other Stockholder Related Rights. The Grantee will have no voting rights or any other rights as a stockholder of the Company (e.g., no rights to cash dividends) with respect to unvested Units until the Units become vested and the Company issues shares of Stock to the Grantee.

11. Delivery of Documents and Notices. Any document relating to participation in the Plan or any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given (except to the extent that this Grant Agreement provides for effectiveness only upon actual receipt of such notice) upon personal delivery, electronic delivery at the e-mail address, if any, provided for the Grantee by the Company or an Affiliate, or upon deposit in the U.S. Post Office or foreign postal service, or with a nationally recognized

5

overnight courier service, with postage and fees prepaid, addressed to the other party at the current address on file with the Company or at such other address as such party may designate in writing from time-to-time to the other party.

11.1 Description of Electronic Delivery. The Plan documents, which may include but do not necessarily include: the Plan, a grant notice, this Grant Agreement, the Plan Prospectus, and any reports of the Company provided generally to the Company’s stockholders, may be delivered to the Grantee electronically. In addition, the Grantee may deliver electronically any grant notice and this Grant Agreement to the Company or to such third party involved in administering the Plan as the Company may designate from time-to-time. Such means of electronic delivery may include but do not necessarily include the delivery of a link to a Company intranet or the internet site of a third party involved in administering the Plan, the delivery of the document via e-mail or such other means of electronic delivery specified by the Company.

11.2 Consent to Electronic Delivery. The Grantee acknowledges that Grantee has read paragraph 11.1 and consents to the electronic delivery of the Plan documents and any grant notice. The Grantee acknowledges that Grantee may receive from the Company a paper copy of any documents delivered electronically at no cost by contacting the Company by telephone or in writing.

12. Administration. This Award Agreement is subject to the terms and conditions of the Plan and the Plan shall in all respects be administered by the Committee in accordance with the terms and provisions of the Plan. The Committee shall have the sole and complete discretion with respect to all matters reserved to it by the Plan and decisions of the majority of the Committee with respect to the Plan and this Award Agreement shall be final and binding upon the Grantee and the Company. In the event of any conflict between the terms and conditions of this Grant Agreement and the Plan, the provisions of the Plan shall control.

13. Continuation of Employment. This Grant Agreement shall not be construed to confer upon the Grantee any right to continue employment with the Company and shall not limit the right of the Company, in its sole and absolute discretion, to terminate Grantee’s employment at any time.

14. Responsibility for Taxes and Withholdings. Regardless of any action the Company or the Grantee’s actual employer (“Employer”) takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Grantee’s participation in the Plan and legally applicable to the Grantee (“Tax-Related Items”), the Grantee acknowledges that the ultimate liability for all Tax-Related Items is and remains the Grantee’s responsibility and may exceed the amount actually withheld by the Company or the Employer. The Grantee further acknowledges that the Company and/or the Employer: (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units, including the grant of the Units, the vesting of Units, the conversion of the Units into shares or the receipt of an equivalent cash payment, the subsequent sale of any shares acquired at vesting and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate the Grantee’s liability for Tax-Related

6

Items or achieve any particular tax result. Further, if the Grantee has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Grantee acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

Prior to any relevant taxable or tax withholding event, as applicable, the Grantee shall pay, or make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all Tax-Related Items. In this regard, pursuant to Article 17 of the Plan, if permissible under local law and unless otherwise provided by the Committee prior to the vesting of the shares, the Grantee authorizes the Company or the Employer, or their respective agents, to withhold all applicable Tax-Related Items in shares of Stock to be issued upon vesting/settlement of the Units. Alternatively, or in addition, the Grantee authorizes the Company and/or the Employer, or their respective agents, at the Company’s discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (i) withholding from the Grantee’s wages or other cash compensation paid to the Grantee by the Company and/or the Employer; (ii) withholding from proceeds of the sale of shares of Stock acquired upon vesting/settlement of the Units either through a voluntary sale or through a mandatory sale arranged by the Company (on the Grantee’s behalf pursuant to this authorization); (iii) personal check or other cash equivalent acceptable to the Company; or (iv) any other means as determined appropriate by the Company or the Committee, including, without limitation, election by Grantee to forfeit a portion of the Vested shares on the vesting date as consideration for Tax-Related Items.

The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding a number of shares of Stock as described herein, for tax purposes, the Grantee shall be deemed to have been issued the full number of shares of Stock subject to the Award, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items due as a result of the Grantee’s participation in the Plan.

Finally, the Grantee shall pay to the Company or to the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of the Grantee’s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver shares or the proceeds of the sale of shares of Stock if the Grantee fails to comply with his or her obligation in connection with the Tax-Related Items.

15. Amendments. Unless otherwise provided in the Plan or this Grant Agreement, this Grant Agreement may be amended only by a written agreement executed by the Company and the Grantee.

16. Integrated Agreement. Any grant notice, this Grant Agreement and the Plan shall constitute the entire understanding and agreement of the Grantee and the Company with respect to the subject matter contained herein or therein and supersedes any prior agreements, understandings, restrictions, representations, or warranties between the Grantee and the Company with respect to such subject matter other than those as set forth or provided for herein

7

or therein. To the extent contemplated herein or therein, the provisions of any grant notice and this Grant Agreement shall survive any settlement of the Award and shall remain in full force and effect.

17. Severability. If one or more of the provisions of this Grant Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Grant Agreement to be construed so as to foster the intent of this Grant Agreement and the Plan.

18. Counterparts. Any grant notice and this Grant Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

19. Governing Law and Venue. This Grant Agreement shall be interpreted and administered under the laws of the State of Delaware. For purposes of litigating any dispute that arises under this grant or this Award, the parties hereby submit to and consent to the jurisdiction of the State of California, agree that such litigation shall be conducted in the courts of Orange County, California, or the federal courts for the United States for the District of California, where this grant is made and/or to be performed.

20. Other. The Grantee represents that the Grantee has read and is familiar with the provisions of the Plan and this Grant Agreement, and hereby accepts the Award subject to all of their terms and conditions.

21. Section 409A Compliance. The Company believes, but does not and cannot warrant or guaranty, that the payments due pursuant to this Grant Agreement qualify for the short-term deferral exception to Section 409A of the Code as set forth in Treasury Regulation Section 1.409A-1(b)(4). Notwithstanding anything to the contrary in this Grant Agreement, if the Company determines that neither the short-term deferral exception nor any other exception to Section 409A applies to the payments due pursuant to this Grant Agreement, to the extent any payments are due on the Grantee’s termination of employment, the term “termination of employment” shall mean “separation from service” as defined in Treasury Regulation Section 1.409A-1(h). In addition, if Grantee is a “specified employee” (as defined in Treasury Regulation Section 1.409A-1(i)) and any payments due pursuant to this Award Agreement are payable on the Grantee’s “separation from service,” then such payments shall be paid on the first business day following the expiration of the six month period following the Grantee’s “separation from service.” This Grant Agreement shall be operated in compliance with Section 409A or an exception thereto and each provision of this Grant Agreement shall be interpreted, to the extent possible, to comply with Section 409A or to qualify for an applicable exception. The Grantee remains solely responsible for any adverse tax consequences imposed upon the Grantee by Section 409A.

22. Confidentiality. The Grantee acknowledges and agrees that the terms of this Award Agreement are considered proprietary information of the Company. The Grantee hereby

8

agrees that Grantee shall maintain the confidentiality of these matters to the fullest extent permitted by law and shall not disclose them to any third party. If the Grantee violates this confidentiality provision, without waiving any other remedy available, the Company may revoke this Award without further obligation or liability, and the Grantee may be subject to disciplinary action, up to and including the Company’s termination of the Grantee’s employment for Cause.

23. Appendix. Notwithstanding any provisions in this Grant Agreement, the grant of the Units shall be subject to any special terms and conditions set forth in any appendix (or any appendices) to this Grant Agreement for the Grantee’s country (the “Appendix”). Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan. The Appendix constitutes part of this Grant Agreement.

24. Imposition of Other Requirements. The Company reserves the right to impose other requirements on the Grantee’s participation in the Plan, on the Units and on any shares of Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Grantee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Further, the Award and profits under this Grant Agreement are subject to the Company’s compensation recovery policy or policies (and related Company practices) as such may be in effect from time-to-time, as a result of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as amended, and similar or related laws, rules and regulations.

9

IN WITNESS WHEREOF, the Company has caused this Grant Agreement to be signed by its duly authorized representative and the Grantee has signed this Grant Agreement as of the date first written above.

AMERICAN VANGUARD CORPORATION
By:
	Its:
GRANTEE
By:

10

EX-31.1

Exhibit 31.1

AMERICAN VANGUARD CORPORATION

CHIEF EXECUTIVE OFFICER CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Eric G. Wintemute, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of American Vanguard Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in according with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosures controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: July 31, 2014	/S/    ERIC G. WINTEMUTE
	Eric G. Wintemute Chief Executive Officer and Chairman of the Board

EX-31.2

Exhibit 31.2

AMERICAN VANGUARD CORPORATION

CHIEF FINANCIAL OFFICER CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David T. Johnson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of American Vanguard Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in according with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosures controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: July 31, 2014	/S/    DAVID T. JOHNSON
	David T. Johnson Chief Financial Officer & Principal Accounting Officer

EX-32.1

Exhibit 32.1

AMERICAN VANGUARD CORPORATION

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of American Vanguard Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2014 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002 that based on their knowledge (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (2) the information contained in the Report fairly represents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in the Report.

/S/    ERIC G. WINTEMUTE

Eric G. Wintemute

Chief Executive Officer and Chairman of the Board

/S/    DAVID T. JOHNSON

David T. Johnson

Chief Financial Officer & Principal Accounting Officer

July 31, 2014

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to American Vanguard Corporation and will be retained by American Vanguard Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.

XML

Summary of Business Sales Segmentation as per Location (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net Sales:
Net sales	$ 68,313	$ 86,761	$ 149,408	$ 208,298
US
Net Sales:
Net sales	50,094	67,837	108,050	170,942
International
Net Sales:
Net sales	$ 18,219	$ 18,924	$ 41,358	$ 37,356

XML

Legal Proceedings - Additional Information (Detail)	0 Months Ended	6 Months Ended
	Jun. 16, 2014 Mark Spence v. A.W. Chesterton Company et al. Defendant	Jun. 30, 2014 Former Banana Workers Case Person
Loss Contingencies [Line Items]
Number of lawsuits filed		100
Lawsuits filed in United States		15
Number of claimants		2,700
Number of defendants	46
Company actions	The Company is unaware of having ever sold any product or packaging that incorporated asbestos and believes that this claim has no merit. We plan to defend the matter vigorously. The Company believes that a loss is neither probable nor reasonably estimable and has not established a loss contingency for the matter.

XML

Summary of Option Activity (Parenthetical) (Detail) (USD $)	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option exercised	$ 7.50	$ 7.50

XML

Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances (Detail) (Fair Value, Measurements, Recurring, Cash Flow Hedging, Level 2, USD $) In Thousands, unless otherwise specified	Jun. 30, 2014		Dec. 31, 2013
Fair Value, Measurements, Recurring | Cash Flow Hedging | Level 2
Liability:
Interest rate derivative financial instruments	$ 283	[1]	$ 564	[1]

[1] Includes accrued interest expense

XML

Derivative Liabilities Recognized in Current Installments of Other Liabilities in Condensed Consolidated Balance Sheets (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014
Derivatives, Fair Value [Line Items]
Gross Amounts of Recognized Liabilities	$ (283)
Gross Amounts Offset in the Statement of Financial Position
Net Amounts of Liabilities Presented in the Statement of Financial Position	(283)
Financial Instruments
Cash Collateral Pledged
Net Amount	(283)
Bank of the West
Derivatives, Fair Value [Line Items]
Gross Amounts of Recognized Liabilities	(283)
Gross Amounts Offset in the Statement of Financial Position
Net Amounts of Liabilities Presented in the Statement of Financial Position	(283)
Financial Instruments
Cash Collateral Pledged
Net Amount	$ (283)

XML

Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2014

Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances

The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of June 30, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:

	Fair Value Measurements Using Input Type
	Level 1		Level 2		Level 3
As of June 30, 2014:
Liability:
Interest rate derivative financial instruments (1)	$	—	$	283	$	—
As of December 31, 2013:
Liability:
Interest rate derivative financial instruments (1)	$	—	$	564	$	—

(1) Includes accrued interest expense

XML

Equity Investment - Additional Information (Detail) In Thousands, except Share data, unless otherwise specified	0 Months Ended	1 Months Ended	3 Months Ended	6 Months Ended			1 Months Ended
	Mar. 25, 2013 USD ($)	Feb. 28, 2014 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Mar. 25, 2013	Feb. 28, 2014 TyraTech Inc. USD ($)	Feb. 28, 2014 TyraTech Inc. GBP (£)
Equity Method Investments [Line Items]
Equity investment	$ 3,687				$ 3,687
Equity investment ownership position			23.96%	23.96%		29.27%
Shares issued by equity investee							37,391,763	37,391,763
Amount raised by equity investee on shares issued				1,196	527		3,100	1,870
Gain from the dilution of the ownership position		256		256
Loss from equity method investment			68	396
Carrying value of equity investment			2,561	2,561
Quoted market value of equity investment			$ 7,049	$ 7,049

XML

Subsequent event

6 Months Ended

Jun. 30, 2014

Subsequent event

18. Subsequent event —As of July 18, 2014, AMVAC Chemical Corporation (“AMVAC”), our principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. Under the First Amendment, the Consolidated Funded Debt Ratio has been increased for the third and fourth quarters of 2014 and the first quarter of 2015, and, further, borrowers are permitted to pay cash dividends to shareholders during the first and second quarters of 2015 notwithstanding prior net income levels.

XML

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) (USD $) In Thousands, except Share data, unless otherwise specified				6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2014 Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	460,879	478,379	561,029	460,879
Number of Shares, Expected to Vest				460,879
Number of Shares, Exercisable				457,546
Weighted Average Exercise Price, Outstanding	$ 7.81	$ 7.80	$ 7.76	$ 7.81
Weighted Average Exercise Price, Expected to Vest				$ 7.81
Weighted Average Exercisable, Exercise Price	$ 7.77	$ 7.74	$ 7.70	$ 7.77
Weighted Average Remaining Life, Outstanding				77 months
Weighted Average Remaining Contractual Life, Expected to Vest				77 months
Weighted Average Remaining Contractual Life, Exercisable				77 months
Intrinsic Value, Outstanding				$ 2,503
Intrinsic Value, Expected to Vest				2,503
Intrinsic Value, Exercisable				$ 2,503

XML

Earnings Per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Components Of Basic And Diluted Earning Per Share [Line Items]
Potentially dilutive stock options to purchase shares	2,385	0	4,591	0

XML

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014 Segment
Business reportable segment	1

XML

Summary of Non-Vested Shares (Detail) (Restricted Stock, USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	373,862	376,702	376,702
Number of Shares, Granted	240,724		240,724	154,114
Number of Shares, Vested	(23,478)	(1,000)		(8,230)
Number of Shares, Forfeited		(1,840)
Number of Shares, Ending Balance	591,108	373,862	591,108
Weighted Average Grant-Date Fair Value, Beginning balance	$ 24.83	$ 24.85	$ 24.85
Weighted Average Grant-Date Fair Value, Granted	$ 14.81		$ 14.81	$ 31.22
Weighted Average Grant-Date Fair Value, Vested	$ 13.84	$ 31.83
Weighted Average Grant-Date Fair Value, Forfeited		$ 24.23
Weighted Average Grant-Date Fair Value, Ending balance	$ 21.19	$ 24.83	$ 21.19

XML

Summary of Option Activity (Detail) (USD $)	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	478,379	561,029
Incentive Stock Option Plans, Option exercised	(17,500)	(82,650)
Incentive Stock Option Plans, Ending balance	460,879	478,379
Weighted Average Price Per Share, Beginning balance	$ 7.80	$ 7.76
Weighted Average Price Per Share, Option exercised	$ 7.50	$ 7.50
Weighted Average Price Per Share, Ending balance	$ 7.81	$ 7.80
Exercisable Weighted Average Price Per Share, Beginning balance	$ 7.74	$ 7.70
Exercisable Weighted Average Price Per Share, Ending balance	$ 7.77	$ 7.74

XML

Property, plant and equipment

6 Months Ended

Jun. 30, 2014

Property, plant and equipment

2. Property, plant and equipment (at cost) at June 30, 2014 and December 31, 2013 consists of the following:

	June 30, 2014			December 31, 2013
Land	$	2,458		$	2,458
Buildings and improvements		14,355			14,167
Machinery and equipment		105,815			94,184
Office furniture, fixtures and equipment		9,980			9,717
Automotive equipment		288			278
Construction in progress		2,477			10,615
		135,373			131,419
Less accumulated depreciation		(83,752	)		(78,951	)
	$	51,621		$	52,468

XML

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Extinguishment of Debt [Line Items]
Long Term debt	$ 86,091	$ 51,676
Short-term	70	69
Total indebtedness	86,161	51,745
Revolving line of credit
Extinguishment of Debt [Line Items]
Long Term debt	86,000	51,550
Total indebtedness	86,000	51,550
Notes payable
Extinguishment of Debt [Line Items]
Long Term debt	91	126
Short-term	70	69
Total indebtedness	$ 161	$ 195

XML

Cash Dividends (Tables)

6 Months Ended

Jun. 30, 2014

Cash Dividends

The Company has issued the following cash dividends in the periods covered by this Form 10-Q:

Declaration Date	Distribution Date	Record Date	Dividend Per Share		Total Paid
June 9, 2014	July 17, 2014	July 3, 2014	$	0.05	$	1,420
March 10, 2014	April 18, 2014	April 4, 2013	$	0.05	$	1,417
Total			$	0.10	$	2,837
June 10, 2013	July 19, 2013	July 5, 2013	$	0.05	$	1,413
March 11, 2013	April 19, 2013	April 5, 2013	$	0.07	$	1,976
Total			$	0.12	$	3,389

XML

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2014

Summary of Business Sales Segmentation as per Product

Selective enterprise information is as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Net sales:
Insecticides	$	34,524	$	39,218	$	80,961	$	118,085
Herbicides/soil fumigants/fungicides		13,926		24,699		36,857		57,685
Other, including plant growth regulators		8,929		13,228		12,736		16,919
		57,379		77,145		130,554		192,689
Non-crop		10,934		9,616		18,854		15,609
	$	68,313	$	86,761	$	149,408	$	208,298

Summary of Business Sales Segmentation as per Location

Three Months Ended June 30					Six Months Ended June 30
	2014		2013			2014		2013
Net Sales:
US sales	$	50,094	$	67,837		$	108,050	$	170,942
International sales		18,219		18,924			41,358		37,356
	$	68,313	$	86,761		$	149,408	$	208,298

XML

Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Loss (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ (861)	$ (1,048)
Other comprehensive loss before reclassifications	84	28
Amounts reclassified from AOCI	153	159
Ending Balance	(624)	(861)
Interest Rate Swap
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(204)	(340)
Other comprehensive loss before reclassifications	(8)	(23)
Amounts reclassified from AOCI	153	159
Ending Balance	(59)	(204)
Accumulated Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(657)	(708)
Other comprehensive loss before reclassifications	92	51
Ending Balance	$ (565)	$ (657)

XML

Indebtedness - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014 Contract	Jun. 30, 2013
Debt Instrument [Line Items]
Number of Interest rate swap contract outstanding	1
Losses in other comprehensive income expected to be reclassified to earnings	$ (59,000)
Duration of losses in other comprehensive income expected to be reclassified to earnings	12 months
Fixed interest rate for interest rate swap contract	3.39%	3.39%
Interest rate swap, start date	Mar. 30, 2011
Interest rate swap, termination date	Dec. 31, 2014
Maximum
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement	64,057,000
Cash Flow Hedging | Interest Rate Swap
Debt Instrument [Line Items]
Notional amount of interest rate swap	33,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Senior secured credit facility	200,000,000
Senior secured credit facility term	5 years
Revolving Credit Facility | Accordion Feature
Debt Instrument [Line Items]
Senior secured credit facility	$ 100,000,000

XML

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2014

Components of Basic and Diluted Earnings Per Share

The components of basic and diluted earnings per share were as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Numerator:
Net income attributable to AVD	$	145	$	8,386	$	2,304	$	25,301
Denominator:
Weighted averages shares outstanding-basic		28,408		28,295		28,404		28,280
Dilutive effect of stock options and grants		387		591		473		604
		28,795		28,886		28,877		28,884

XML

Indebtedness (Tables)

6 Months Ended

Jun. 30, 2014

Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets

The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at June 30, 2014 and December 31, 2013. These are summarized in the following table:

Indebtedness	June 30, 2014						December 31, 2013
$000’s	Long-term		Short-term		Total		Long-term		Short-term		Total
Revolving line of credit	$	86,000	$	—	$	86,000	$	51,550	$	—	$	51,550
Notes payable		91		70		161		126		69		195
Total indebtedness	$	86,091	$	70	$	86,161	$	51,676	$	69	$	51,745

Summary of Effect of Derivative Instruments on Statements of Operations and Comprehensive Income

The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and six months ended June 30, 2014.

For the three months ended June 30, 2014 and 2013

Derivatives in ASC 815 Cash Flow Hedging Relationships	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)						Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)
	2014			2013					2014			2013					2014		2013
Interest rate contracts	$	(8	)	$	(7	)		Interest Expense	$	(153	)	$	(181	)		Interest Expense	$	—	$	—
Total	$	(8	)	$	(7	)			$	(153	)	$	(181	)			$	—	$	—

For the six months ended June 30, 2014 and 2013

Derivatives in ASC 815 Cash Flow Hedging Relationships	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)						Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)
	2014			2013					2014			2013					2014		2013
Interest rate contracts	$	(31	)	$	(14	)		Interest Expense	$	(312	)	$	(366	)		Interest Expense	$	—	$	(1	)
Total	$	(31	)	$	(14	)			$	(312	)	$	(366	)			$	—	$	(1	)

Derivative Liabilities Recognized In Current Installments of Other Liabilities in Condensed Consolidated Balance Sheets

The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:

									Gross Amounts Not Offset in the Statement of Financial Position
Description	Gross Amounts of Recognized Liabilities			Gross Amounts Offset in the Statement of Financial Position		Net Amounts of Liabilities Presented in the Statement of Financial Position			Financial Instruments		Cash Collateral Pledged		Net Amount
Derivatives by counterparty:
Bank of the West	$	(283	)	$	—	$	(283	)	$	—	$	—	$	(283	)
Total	$	(283	)	$	—	$	(283	)	$	—	$	—	$	(283	)

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2014

Summary of Significant Accounting Policies

1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

XML

Stock Based Compensation Expense (Tables)

6 Months Ended

Jun. 30, 2014

Summary of Option Activity

Option activity within each plan is as follows:

	Incentive Stock Option Plans			Weighted Average Price Per Share		Exercisable Weighted Average Price Per Share
Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.70
Options exercised, $7.50		(82,650	)		7.50
Balance outstanding, March 31, 2014		478,379		$	7.80	$	7.74
Options exercised, $7.50		(17,500	)		7.50
Balance outstanding, June 30, 2014		460,879		$	7.81	$	7.77

Summary of Stock Options Summarized by Exercise Price

Information relating to stock options at June 30, 2014 summarized by exercise price is as follows:

	Outstanding Weighted Average						Exercisable Weighted Average
Exercise Price Per Share	Shares		Remaining Life (Months)		Exercise Price		Shares		Exercise Price
Incentive Stock Option Plan:
$7.50		434,200		77	$	7.50		434,200	$	7.50
$11.32—$14.75		26,679		74	$	12.90		23,346	$	12.85
		460,879			$	7.81		457,546	$	7.77

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding

The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2014 was as follows:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Months)		Intrinsic Value (thousands)
As of June 30, 2014:
Incentive Stock Option Plans:
Outstanding		460,879	$	7.81		77	$	2,503
Expected to Vest		460,879	$	7.81		77	$	2,503
Exercisable		457,546	$	7.77		77	$	2,503

Summary of Non-Vested Shares

Restricted Shares—A status summary of non-vested shares as of and for the six months ended June 30, 2014 is presented below:

	Number of Shares			Weighted Average Grant- Date Fair Value
Nonvested shares at December 31, 2013		376,702		$	24.85
Vested		(1,000	)	$	31.83
Forfeited		(1,840	)	$	24.23
Nonvested shares at March 31, 2014		373,862		$	24.83
Granted		240,724		$	14.81
Vested		(23,478	)	$	13.84
Forfeited		—		$	—
Nonvested shares at June 30, 2014		591,108		$	21.19

Performance Shares

Summary of Non-Vested Shares

Performance Based Shares—A status summary of non-vested performance based shares as of and for the six months ended June 30, 2014 is presented below:

	Number of Shares		Weighted Average Grant- Date Fair Value
Nonvested shares at December 31, 2013		24,637	$	28.43
Vested		—	$	—
Forfeited		—	$	—
Nonvested shares at March 31, 2014		24,637	$	28.43
Granted		79,270	$	14.23
Vested		—	$	—
Forfeited		—	$	—
Nonvested shares at June 30, 2014		103,907	$	17.60

XML

Cash Dividends (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Dividends [Line Items]
Cash dividend declared	$ 0.10	$ 0.12
Cash dividends paid	$ 2,837	$ 3,389
Second Quarter Dividend
Dividends [Line Items]
Cash dividend declaration Date	Jun. 09, 2014	Jun. 10, 2013
Cash dividend distributed date	Jul. 17, 2014	Jul. 19, 2013
Cash dividend record date	Jul. 03, 2014	Jul. 05, 2013
Cash dividend declared	$ 0.05	$ 0.05
Cash dividends paid	1,420	1,413
First Quarter Dividend
Dividends [Line Items]
Cash dividend declaration Date	Mar. 10, 2014	Mar. 11, 2013
Cash dividend distributed date	Apr. 18, 2014	Apr. 19, 2013
Cash dividend record date	Apr. 04, 2013	Apr. 05, 2013
Cash dividend declared	$ 0.05	$ 0.07
Cash dividends paid	$ 1,417	$ 1,976

XML

Status Summary of Non-Vested Shares (Detail) (Performance Shares, USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	24,637	24,637	24,637
Number of Shares, Granted	79,270		79,270	26,942
Weighted Average Grant-Date Fair Value, Granted	$ 14.23
Number of Shares, Vested
Number of Shares, Forfeited
Number of Shares, Ending Balance	103,907	24,637	103,907
Weighted Average Grant-Date Fair Value, Beginning balance	$ 28.43	$ 28.43	$ 28.43
Weighted Average Grant-Date Fair Value, Vested
Weighted Average Grant-Date Fair Value, Forfeited
Weighted Average Grant-Date Fair Value, Ending balance	$ 17.60	$ 28.43	$ 17.60

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales	$ 68,313	$ 86,761	$ 149,408	$ 208,298
Cost of sales	42,253	44,695	94,443	112,451
Gross profit	26,060	42,066	54,965	95,847
Operating expenses	25,337	29,169	50,280	56,798
Operating income	723	12,897	4,685	39,049
Interest expense	857	701	1,488	1,248
Less interest capitalized	(13)	(31)	(31)	(225)
(Loss) income before income taxes and loss on equity investment	(121)	12,227	3,228	38,026
Income taxes (benefit) expense	(160)	3,961	856	12,941
Income before loss on equity investment	39	8,266	2,372	25,085
Deduct net loss from equity method investment	(68)		(396)
Net (loss) income	(29)	8,266	1,976	25,085
Add back net loss attributable to non-controlling interest	174	120	328	216
Net income attributable to American Vanguard Corporation	145	8,386	2,304	25,301
Change in fair value of interest rate swaps	145	174	281	352
Foreign currency translation adjustment	92	(476)	143	(69)
Comprehensive income	$ 382	$ 8,084	$ 2,728	$ 25,584
Earnings per common share-basic	$ 0.01	$ 0.29	$ 0.08	$ 0.89
Earnings per common share-assuming dilution	$ 0.01	$ 0.29	$ 0.08	$ 0.88
Weighted average shares outstanding-basic	28,408	28,295	28,404	28,280
Weighted average shares outstanding-assuming dilution	28,795	28,886	28,877	28,884

XML

Summary of Effect of Derivative Instruments on Statements of Operations and Comprehensive Income (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	$ (8)	$ (7)	$ (31)	$ (14)
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	(153)	(181)	(312)	(366)
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)				(1)
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(8)	(7)	(31)	(14)
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts | Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	(153)	(181)	(312)	(366)
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)				$ (1)

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) (USD $)	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Cash dividends on common stock, per share	$ 0.05	$ 0.05

XML

Summary of Property, Plant and Equipment (at Cost) (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 135,373	$ 131,419
Less accumulated depreciation	(83,752)	(78,951)
Total Property, plant and equipment	51,621	52,468
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	14,355	14,167
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	105,815	94,184
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	9,980	9,717
Automotive equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	288	278
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 2,477	$ 10,615

XML

Accumulated Other Comprehensive Loss

6 Months Ended

Jun. 30, 2014

Accumulated Other Comprehensive Loss

15. Accumulated Other Comprehensive Loss—

The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:

	Interest Rate Swap			FX Translation			Total
Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
Other comprehensive loss before reclassifications		(23	)		51			28
Amounts reclassified from AOCI		159			—			159
Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)
Other comprehensive loss before reclassifications		(8	)		92			84
Amounts reclassified from AOCI		153			—			153
Balance, June 30, 2014	$	(59	)	$	(565	)	$	(624	)

XML

Components of Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Inventory [Line Items]
Finished products	$ 151,269	$ 126,872
Raw materials	23,971	12,958
Total Inventories	$ 175,240	$ 139,830

XML

Income Taxes

6 Months Ended

Jun. 30, 2014

Income Taxes

17. Income Taxes – Income tax expense was $856 for the six months ended June 30, 2014 as compared to $12,941 for the six months ended June 30, 2013. The effective tax rate was 27% in 2014 and 34% in 2013. Income tax benefit was $160 for the three months ended June 30, 2014, and income tax expense was $3,961 for the three months ended June 30, 2013.

The effective tax rate for the three months ended June 30, 2014 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income	$ 1,976	$ 25,085
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization of fixed and intangible assets	7,996	7,461
Amortization of other long term assets	3,027	1,802
Amortization of discounted liabilities	175	86
Stock-based compensation	1,806	1,747
Tax benefit from exercise of stock options	(262)	(57)
Loss from equity method investment	396
Gain on dilution of equity method investment	(256)
Changes in assets and liabilities associated with operations:
(Increase) decrease in net receivables	(1,025)	8,513
Increase in inventories	(35,410)	(39,199)
Increase in prepaid expenses and other assets	(5,069)	(9,837)
Decrease (increase) in income tax receivable	120	(1,404)
Decrease in accounts payable	(16,521)	(8,532)
Decrease in deferred revenue	(2,276)	(20,149)
Increase in other payables and accrued expenses	16,264	54,529
Net cash (used in) provided by operating activities	(29,059)	20,045
Cash flows from investing activities:
Capital expenditures	(3,954)	(8,360)
Investment		(3,687)
Net cash used in investing activities	(3,954)	(12,047)
Cash flows from financing activities:
Net borrowings under line of credit agreement	34,450	40,750
Payments on long-term debt		(46,000)
Payments on other long-term liabilities	(1,109)	(1,238)
Tax benefit from exercise of stock options	262	57
Decrease in other notes payable		(6,154)
Repurchases of common stock	(1,531)
Payment of cash dividends	(2,836)	(1,976)
Proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	1,196	527
Net cash provided by (used in) financing activities	30,432	(14,034)
Net decrease in cash and cash equivalents	(2,581)	(6,036)
Cash and cash equivalents at beginning of period	6,680	38,476
Effect of exchange rate changes on cash	90	(26)
Cash and cash equivalents as of the end of the period	$ 4,189	$ 32,414

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 4,189	$ 6,680
Receivables:
Trade, net of allowance for doubtful accounts of $414 and $392, respectively	73,239	74,060
Other	2,738	892
Total receivables	75,977	74,952
Inventories	175,240	139,830
Prepaid expenses	14,049	11,435
Income taxes receivable	10,230	10,088
Deferred income tax assets	6,521	6,521
Total current assets	286,206	249,506
Property, plant and equipment, net	51,621	52,468
Intangible assets, net of applicable amortization	103,865	107,007
Other assets	37,750	38,462
Total assets	479,442	447,443
Current liabilities:
Current installments of long-term debt	70	69
Current installments of other liabilities	1,440	2,132
Accounts payable	23,900	40,702
Deferred revenue	1,512	3,788
Accrued program costs	74,359	53,630
Accrued expenses and other payables	5,996	10,178
Total current liabilities	107,277	110,499
Long-term debt, excluding current installments	86,091	51,676
Other liabilities, excluding current installments	3,981	4,143
Deferred income tax liabilities	23,002	23,330
Total liabilities	220,351	189,648
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued	0	0
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,528,400 shares at June 30, 2014 and 31,092,782 shares at December 31, 2013	3,153	3,109
Additional paid-in capital	63,380	60,160
Accumulated other comprehensive loss	(624)	(1,048)
Retained earnings	201,937	202,470
Total stockholders' equity including treasury stock	267,846	264,691
Less treasury stock, at cost, 2,450,634 shares at June 30, 2014 and 2,380,634 shares at December 31, 2013	(8,269)	(6,738)
American Vanguard Corporation stockholders' equity	259,577	257,953
Non-controlling interest	(486)	(158)
Total stockholders' equity	259,091	257,795
Total liabilities and stockholders' equity	$ 479,442	$ 447,443

XML

Comprehensive Income

6 Months Ended

Jun. 30, 2014

Comprehensive Income

10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the six month period ended June 30, 2014, total comprehensive income consisted of net income attributable to AVD, the change in fair value of interest rate swaps and foreign currency translation adjustments.

XML

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 24, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	0000005981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		29,080,871

XML

Stock Based Compensation Expense

6 Months Ended

Jun. 30, 2014

Stock Based Compensation Expense

11. Stock Based Compensation Expense—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan based on estimated fair values.

Stock Options—During the six months ended June 30, 2014, the Company did not grant any employees options to acquire shares of common stock.

Option activity within each plan is as follows:

	Incentive Stock Option Plans			Weighted Average Price Per Share		Exercisable Weighted Average Price Per Share
Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.70
Options exercised, $7.50		(82,650	)		7.50
Balance outstanding, March 31, 2014		478,379		$	7.80	$	7.74
Options exercised, $7.50		(17,500	)		7.50
Balance outstanding, June 30, 2014		460,879		$	7.81	$	7.77

Information relating to stock options at June 30, 2014 summarized by exercise price is as follows:

	Outstanding Weighted Average						Exercisable Weighted Average
Exercise Price Per Share	Shares		Remaining Life (Months)		Exercise Price		Shares		Exercise Price
Incentive Stock Option Plan:
$7.50		434,200		77	$	7.50		434,200	$	7.50
$11.32—$14.75		26,679		74	$	12.90		23,346	$	12.85
		460,879			$	7.81		457,546	$	7.77

The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2014 was as follows:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Months)		Intrinsic Value (thousands)
As of June 30, 2014:
Incentive Stock Option Plans:
Outstanding		460,879	$	7.81		77	$	2,503
Expected to Vest		460,879	$	7.81		77	$	2,503
Exercisable		457,546	$	7.77		77	$	2,503

During the six months ended June 30, 2014 and 2013, the Company recognized stock-based compensation expense, excluding expense associated with modifications, related to stock options of $21 and $423, respectively.

As of June 30, 2014, the Company had no unamortized stock-based compensation expenses related to unvested stock options outstanding. Stock-based compensation expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Restricted Shares—A status summary of non-vested shares as of and for the six months ended June 30, 2014 is presented below:

	Number of Shares			Weighted Average Grant- Date Fair Value
Nonvested shares at December 31, 2013		376,702		$	24.85
Vested		(1,000	)	$	31.83
Forfeited		(1,840	)	$	24.23
Nonvested shares at March 31, 2014		373,862		$	24.83
Granted		240,724		$	14.81
Vested		(23,478	)	$	13.84
Forfeited		—		$	—
Nonvested shares at June 30, 2014		591,108		$	21.19

Restricted stock grants — During the six months ended June 30, 2014, the Company granted a total of 240,724 shares of common stock. Of these, 23,478 shares vest immediately, and the balance will cliff vest after three years of service. The shares granted in 2014 were average fair valued at $14.81 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.

During the six months ended June 30, 2013, the Company granted a total of 154,114 shares of common stock. Of these, 3,000 shares will vest one-third each year on the anniversaries of the employee’s employment date, 8,230 shares vest immediately, and the balance will cliff vest after three years of service. The shares granted in 2013 were average fair valued at $31.22 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.

During the six months ended June 30, 2014 and 2013, the Company recognized stock-based compensation expense related to restricted shares of $1,819 and $1,297, respectively.

As of June 30, 2014, the Company had approximately $7,153 of unamortized stock-based compensation expenses related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.1 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Performance Based Shares—A status summary of non-vested performance based shares as of and for the six months ended June 30, 2014 is presented below:

	Number of Shares		Weighted Average Grant- Date Fair Value
Nonvested shares at December 31, 2013		24,637	$	28.43
Vested		—	$	—
Forfeited		—	$	—
Nonvested shares at March 31, 2014		24,637	$	28.43
Granted		79,270	$	14.23
Vested		—	$	—
Forfeited		—	$	—
Nonvested shares at June 30, 2014		103,907	$	17.60

Performance Based Shares — During the six months ended June 30, 2014, the Company granted a total of 79,270 performance based shares that will cliff vest on May 23, 2017, provided that recipient is continuously employed by the Company during the vesting period. 80% of these performance based shares are based upon financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30% for the period commencing April 1, 2014 and ending December 31, 2016; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goal measures the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The shareholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2014 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.

During the six months ended June 30, 2013, the Company granted a total of 26,942 performance based shares that will cliff vest after three years of service. 80% of these performance based shares are based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015. Both parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.

The performance based shares related to EBIT and net sales were average fair valued at $14.92 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to AVD stock price were average fair valued at $11.47 per share. The fair value was determined by using the Monte Carlo valuation method. The Company is recognizing as expense the value of these shares over the required service period of three years.

During the six months ended June 30, 2014, the Company recognized a reduction in stock-based compensation expense related to performance based shares of $34. During the six months ended June 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of $26.

As of June 30, 2014, the Company had approximately $1,559 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.6 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Allowance for doubtful accounts	$ 414	$ 392
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,528,400	31,092,782
Treasury stock, shares	2,450,634	2,380,634

XML

Accrued Program Costs

6 Months Ended

Jun. 30, 2014

Accrued Program Costs

5. Accrued Program Costs - In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers as a reduction of sales. The Company describes these payments as “Programs.” Programs are a critical part of doing business in the agricultural chemicals business market place. For accounting purposes, programs are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicator-driven payments made to distributors, retailers or growers at the end of a growing season. Each quarter management compares each sale transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in the terms and conditions attached to each program. If management believes that customers are falling short of their annual goals, then periodic adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at the end of the crop season, at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

XML

Segment Reporting

6 Months Ended

Jun. 30, 2014

Segment Reporting

4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Net sales:
Insecticides	$	34,524	$	39,218	$	80,961	$	118,085
Herbicides/soil fumigants/fungicides		13,926		24,699		36,857		57,685
Other, including plant growth regulators		8,929		13,228		12,736		16,919
		57,379		77,145		130,554		192,689
Non-crop		10,934		9,616		18,854		15,609
	$	68,313	$	86,761	$	149,408	$	208,298
	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Net sales:
US	$	50,094	$	67,837	$	108,050	$	170,942
International		18,219		18,924		41,358		37,356
	$	68,313	$	86,761	$	149,408	$	208,298

XML

Equity Investment

6 Months Ended

Jun. 30, 2014

Equity Investment

16. On March 25, 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, to acquire an ownership position of approximately 29.27%. In February 2014, TyraTech issued 37,391,763 shares and raised approximately £1.87 ($3.1) million. Due to the share issuance, the Company recognized a $256 gain from the dilution of the Company’s ownership position. Following the issuance of these new shares, as of June 30, 2014, the Company’s ownership position in TyraTech was approximately 23.96%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the six months ended June 30, 2014, the Company recognized an operating loss of $396 as a result of the Company’s ownership position in TyraTech.

The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At June 30, 2014, the carrying value of the Company’s investment in TyraTech was $2,561, and the quoted market value of its shareholding was $7,049 based on the London Stock Exchange, Alternative Investment Market (“AIM”).

XML

Legal Proceedings

6 Months Ended

Jun. 30, 2014

Legal Proceedings

12. Legal Proceedings—Summarized below are litigation matters in which there has been material activity or developments during the three month period ended June 30, 2014.

A. DBCP Cases—Delaware

A number of suits have been filed against AMVAC, alleging injury from exposure to the agricultural chemical 1, 2-dibromo-3-chloropropane (“DBCP^®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the United States Environmental Protection Agency (“USEPA”) to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. The USEPA suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product. There are approximately 100 lawsuits, foreign and domestic, filed by former banana workers in which AMVAC has been named as a party. Fifteen of these suits have been filed in the United States (with prayers for unspecified damages) and the remainder has been filed in Nicaragua. All of these actions are in various stages and allege injury from exposure to DBCP, including claims for sterility. Except for the cases described below, there have been no material developments in these matters since the filing of the Company’s Form 10-Q for the period ended March 30, 2014.

In what has been designated as the remaining Hendler-Delaware cases (involving claims for physical injury arising from alleged exposure to DBCP over the course of the late 1960’s through the mid-1980’s on behalf of about 2,700 banana plantation workers from Costa Rica, Ecuador, Guatemala and Panama – more fully described in the Company’s Form 10-K for the period ended December 31, 2013), on May 27, 2014, the district court granted defendant Dole’s motion to dismiss the matter without prejudice on the grounds that the applicable statutes of limitation had expired. In reaching its finding, the court noted that while the Delaware Supreme Court in Blanco had established that Delaware now recognizes the concept of cross-jurisdictional tolling, the factual question as to the tolling of the statute had not been decided by the Blanco court. The court in the Hendler – Delaware cases found that, in fact, the applicable statute of limitations had stopped in 1995. The court left open the possibility that plaintiffs could bring forward evidence that they did not know of their injuries and the causes thereof until a later date, but went on to note that such a showing might be difficult given that many of the symptoms identified by plaintiffs (e.g., vision loss, skin conditions and gastrointestinal problems) are of an obvious nature.

B. Other Matters

AMVAC has been named as one of 46 defendants in an action entitled Mark Spence v. A.W. Chesterton Company et al. which was filed on June 16, 2014 with the Circuit Court of Cook County, Illinois as case number 2014L006394 in which plaintiff alleges to have developed mesothelioma from exposure to asbestos-containing products while working as a construction and lawn care laborer in Illinois over the period 1968 to 1990. Among a laundry list of pipe covers, gaskets, roof shingles and construction materials, plaintiff alleges that he was also exposed to unnamed products of AMVAC including “asbestos contaminated fertilizers, herbicides and other horticultural products.” The Company is unaware of having ever sold any product or packaging that incorporated asbestos and believes that this claim has no merit. We plan to defend the matter vigorously. The Company believes that a loss is neither probable nor reasonably estimable and has not established a loss contingency for the matter.

XML

Indebtedness

6 Months Ended

Jun. 30, 2014

Indebtedness

8. Substantially all of the Company’s assets are pledged as collateral with its banks.

The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at June 30, 2014 and December 31, 2013. These are summarized in the following table:

Indebtedness	June 30, 2014						December 31, 2013
$000’s	Long-term		Short-term		Total		Long-term		Short-term		Total
Revolving line of credit	$	86,000	$	—	$	86,000	$	51,550	$	—	$	51,550
Notes payable		91		70		161		126		69		195
Total indebtedness	$	86,091	$	70	$	86,161	$	51,676	$	69	$	51,745

On June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit up to $200 million and an accordion feature for up to $100 million. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt. See, infra, Item 18 “Subsequent Events” regarding the first amendment to the New Credit Agreement.

At June 30, 2014, the Company had in place one interest rate swap contract with a notional amount of $33,000 that is accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap are reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Losses in other comprehensive income expected to be reclassified to earnings in the coming 12 months are $(59). Amounts recorded in earnings for hedge ineffectiveness for the period ending June 30, 2014 were immaterial.

The Company uses a pay fixed, receive 1Month LIBOR (London Interbank Offered Rate) interest rate swap to manage the interest expense generated by variable rate debt. At June 30, 2014 and 2013, the Company had in place an interest rate swap, the use of which results in a fixed interest rate of 3.39% for the portion of variable rate debt that is covered by the interest rate swap contract. The current interest rate swap contract was put in place on March 30, 2011 and terminates on December 31, 2014.

The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and six months ended June 30, 2014.

For the three months ended June 30, 2014 and 2013

Derivatives in ASC 815 Cash Flow Hedging Relationships	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)						Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)
	2014			2013					2014			2013					2014		2013
Interest rate contracts	$	(8	)	$	(7	)		Interest Expense	$	(153	)	$	(181	)		Interest Expense	$	—	$	—
Total	$	(8	)	$	(7	)			$	(153	)	$	(181	)			$	—	$	—

For the six months ended June 30, 2014 and 2013

Derivatives in ASC 815 Cash Flow Hedging Relationships	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)						Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)
	2014			2013					2014			2013					2014		2013
Interest rate contracts	$	(31	)	$	(14	)		Interest Expense	$	(312	)	$	(366	)		Interest Expense	$	—	$	(1	)
Total	$	(31	)	$	(14	)			$	(312	)	$	(366	)			$	—	$	(1	)

The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2014, the Company met all covenants in that credit facility.

At June 30, 2014, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $64,057 under the credit facility agreement.

The counterparty to the Company’s interest rate derivative financial instrument is Bank of the West, the Company’s primary bank. Pledged cash collateral is not required under the interest rate swap contract. At June 30, 2014, the Company

did not hold any other derivative financial instruments. As a result, there occurs no offsetting of derivative liabilities in the Company’s condensed consolidated financial statements. The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:

									Gross Amounts Not Offset in the Statement of Financial Position
Description	Gross Amounts of Recognized Liabilities			Gross Amounts Offset in the Statement of Financial Position		Net Amounts of Liabilities Presented in the Statement of Financial Position			Financial Instruments		Cash Collateral Pledged		Net Amount
Derivatives by counterparty:
Bank of the West	$	(283	)	$	—	$	(283	)	$	—	$	—	$	(283	)
Total	$	(283	)	$	—	$	(283	)	$	—	$	—	$	(283	)

XML

Cash Dividends

6 Months Ended

Jun. 30, 2014

Cash Dividends

6. The Company has issued the following cash dividends in the periods covered by this Form 10-Q:

Declaration Date	Distribution Date	Record Date	Dividend Per Share		Total Paid
June 9, 2014	July 17, 2014	July 3, 2014	$	0.05	$	1,420
March 10, 2014	April 18, 2014	April 4, 2013	$	0.05	$	1,417
Total			$	0.10	$	2,837
June 10, 2013	July 19, 2013	July 5, 2013	$	0.05	$	1,413
March 11, 2013	April 19, 2013	April 5, 2013	$	0.07	$	1,976
Total			$	0.12	$	3,389

The Company announced the decision to begin making quarterly dividend payments on June 10, 2013. Previously, the Company made semi-annual dividend payments.

XML

Earnings Per Share

6 Months Ended

Jun. 30, 2014

Earnings Per Share

7. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260 Earnings Per Share (“EPS”) requires dual presentation of basic EPS and diluted EPS on the face of our condensed consolidated statements of operations and comprehensive income. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company’s common stock, are exercised.

The components of basic and diluted earnings per share were as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2014		2013		2014		2013
Numerator:
Net income attributable to AVD	$	145	$	8,386	$	2,304	$	25,301
Denominator:
Weighted averages shares outstanding-basic		28,408		28,295		28,404		28,280
Dilutive effect of stock options and grants		387		591		473		604
		28,795		28,886		28,877		28,884

The Company excluded 2,385 stock options from the computation of diluted earnings per share for the three months ended June 30, 2014 and 4,591 stock options from the computation of diluted earnings per share for the six months ended June 30, 2014, because they are anti-dilutive. For the three and six month ended June 30, 2013 no options were excluded from the computation.

XML

Reclassification

6 Months Ended

Jun. 30, 2014

Reclassification

9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the June 30, 2014 presentation.

XML

Accumulated Other Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2014

Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Loss

The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:

	Interest Rate Swap			FX Translation			Total
Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
Other comprehensive loss before reclassifications		(23	)		51			28
Amounts reclassified from AOCI		159			—			159
Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)
Other comprehensive loss before reclassifications		(8	)		92			84
Amounts reclassified from AOCI		153			—			153
Balance, June 30, 2014	$	(59	)	$	(565	)	$	(624	)

XML

Stock Based Compensation Expense - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 34	$ 26
Number of Shares, Granted	79,270		79,270	26,942
Number of shares vested
Number of years of service before cliff vesting				3 years
Weighted Average Grant-Date Fair Value, Granted	$ 14.23
Nonvested unamortized stock-based compensation expense, contractual term			2 years 7 months 6 days
Cliff vesting date			May 23, 2017
Targeted performance percentage	200.00%		200.00%	200.00%
Unamortized stock-based compensation expense	1,559		1,559
Performance Shares | Performance based shares based upon financial performance of earnings before income tax ("EBIT") and net sales goal for the period commencing April 1, 2014 and ending December 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted			$ 14.92
Percentage of shares vesting based on Performance			80.00%
Earnings before income tax goal weight, percentage			50.00%
Net sales goal weight, percentage			30.00%
Performance Shares | Performance based shares based upon AVD stock price appreciation over the course of the period commencing April 1, 2014 and ending December 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted			$ 11.47
Percentage of shares vesting based on Performance			20.00%
Performance Shares | Performance based shares based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance				80.00%
Performance Shares | Performance based shares based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance				20.00%
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			1,819	1,297
Nonvested unamortized stock-based compensation expense, value	7,153		7,153
Number of Shares, Granted	240,724		240,724	154,114
Number of shares vested	23,478	1,000		8,230
Number of years of service before cliff vesting			3 years	3 years
Weighted Average Grant-Date Fair Value, Granted	$ 14.81		$ 14.81	$ 31.22
Nonvested unamortized stock-based compensation expense, contractual term			2 years 1 month 6 days
Restricted Stock | Vest one-third each year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest				3,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			21	423
Nonvested unamortized stock-based compensation expense, value	$ 0		$ 0

XML

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2014

Fair Value of Financial Instruments

14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.

The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of June 30, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:

	Fair Value Measurements Using Input Type
	Level 1		Level 2		Level 3
As of June 30, 2014:
Liability:
Interest rate derivative financial instruments (1)	$	—	$	283	$	—
As of December 31, 2013:
Liability:
Interest rate derivative financial instruments (1)	$	—	$	564	$	—

(1) Includes accrued interest expense

The valuation techniques used to measure the fair value of the derivative financial instruments above in which the counterparties have high credit ratings, were derived from pricing models, such as discounted cash flow techniques, with all significant inputs derived from or corroborated by observable market data. The Company’s discounted cash flow techniques use observable market inputs, such as LIBOR-based yield curves and foreign currency forward rates.

XML

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2014

Summary of Property, Plant and Equipment (at Cost)

Property, plant and equipment (at cost) at June 30, 2014 and December 31, 2013 consists of the following:

	June 30, 2014			December 31, 2013
Land	$	2,458		$	2,458
Buildings and improvements		14,355			14,167
Machinery and equipment		105,815			94,184
Office furniture, fixtures and equipment		9,980			9,717
Automotive equipment		288			278
Construction in progress		2,477			10,615
		135,373			131,419
Less accumulated depreciation		(83,752	)		(78,951	)
	$	51,621		$	52,468

XML

Summary of Stock Options Summarized by Exercise Price (Detail) (USD $)				6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2014 Incentive Stock Option Plan	Jun. 30, 2014 Incentive Stock Option Plan Range One	Jun. 30, 2014 Incentive Stock Option Plan Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercised, Lower Range					$ 7.50	$ 11.32
Options exercised, Upper Range						$ 14.75
Outstanding Weighted Average, Shares				460,879	434,200	26,679
Outstanding Weighted Average, Remaining Life (Months)				77 months	77 months	74 months
Outstanding Weighted Average, Exercise Price	$ 7.81	$ 7.80	$ 7.76	$ 7.81	$ 7.50	$ 12.90
Exercisable Weighted Average, Shares				457,546	434,200	23,346
Exercisable Weighted Average, Exercise Price	$ 7.77	$ 7.74	$ 7.70	$ 7.77	$ 7.50	$ 12.85

XML

Components of Basic and Diluted Earnings Per Share (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:
Net income attributable to AVD	$ 145	$ 8,386	$ 2,304	$ 25,301
Denominator:
Weighted averages shares outstanding-basic	28,408	28,295	28,404	28,280
Dilutive effect of stock options and grants	387	591	473	604
Weighted average shares outstanding-assuming dilution	28,795	28,886	28,877	28,884

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (USD $) In Thousands, except Share data	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive loss	Non- Controlling Interest	Treasury Stock
Beginning Balance at Dec. 31, 2013	$ 257,795	$ 3,109	$ 60,160	$ 202,470	$ (1,048)	$ (158)	$ (6,738)
Beginning Balance (in shares) at Dec. 31, 2013	31,092,782	31,092,782					2,380,634
Stocks issued under ESPP (in shares)		16,446
Stocks issued under ESPP	393	2	391
Cash dividends on common stock	(1,417)			(1,417)
Foreign currency translation adjustment, net	51				51
Stock based compensation	768		768
Change in fair value of interest rate swaps	136				136
Stock options exercised and grants of restricted stock units	625	8	617
Stock options exercised and grants of restricted stock units, Shares		81,678
Excess tax benefits from share based payment arrangements	235		235
Shares repurchased (in shares)							70,000
Shares repurchased	(1,531)						(1,531)
Net income (loss)	2,005			2,159		(154)
Ending Balance at Mar. 31, 2014	259,060	3,119	62,171	203,212	(861)	(312)	(8,269)
Ending Balance (in shares) at Mar. 31, 2014		31,190,906					2,450,634
Cash dividends on common stock	(1,420)			(1,420)
Foreign currency translation adjustment, net	92				92
Stock based compensation	1,038		1,038
Change in fair value of interest rate swaps	145				145
Stock options exercised and grants of restricted stock units	178	34	144
Stock options exercised and grants of restricted stock units, Shares		337,494
Excess tax benefits from share based payment arrangements	27		27
Net income (loss)	(29)			145		(174)
Ending Balance at Jun. 30, 2014	$ 259,091	$ 3,153	$ 63,380	$ 201,937	$ (624)	$ (486)	$ (8,269)
Ending Balance (in shares) at Jun. 30, 2014	31,528,400	31,528,400					2,450,634

XML

Inventories

6 Months Ended

Jun. 30, 2014

Inventories

3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:

	June 30, 2014		December 31, 2013
Finished products	$	151,269	$	126,872
Raw materials		23,971		12,958
	$	175,240	$	139,830

XML

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Line Items]
Income taxes (benefit) expense	$ (160)	$ 3,961	$ 856	$ 12,941
Effective tax rate			27.00%	34.00%

XML

Inventories (Tables)

6 Months Ended

Jun. 30, 2014

Components of Inventories

The components of inventories consist of the following:

	June 30, 2014		December 31, 2013
Finished products	$	151,269	$	126,872
Raw materials		23,971		12,958
	$	175,240	$	139,830

XML

Summary of Business Sales Segmentation as per Product (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net Sales:
Total Crop	$ 57,379	$ 77,145	$ 130,554	$ 192,689
Non-crop	10,934	9,616	18,854	15,609
Net sales	68,313	86,761	149,408	208,298
Insecticides
Net Sales:
Total Crop	34,524	39,218	80,961	118,085
Herbicides/Soil Fumigants/Fungicides
Net Sales:
Total Crop	13,926	24,699	36,857	57,685
Other, Including Plant Growth Regulators
Net Sales:
Total Crop	$ 8,929	$ 13,228	$ 12,736	$ 16,919

XML

Recently Issued Accounting Guidance

6 Months Ended

Jun. 30, 2014

Recently Issued Accounting Guidance

13. Recently Issued Accounting Guidance—In June 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017.

In February 2013, FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012. The Company adopted this standard effective January 1, 2013.